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Abstract 
Colorectal cancer is the second highest cause of cancer deaths in the UK. The 
transcriptional regulator c-Myc and transmembrane protein CD44 are reported 
to be associated with cancer stem cells and epithelial to mesenchymal 
transition, which have both been linked to poor outcomes. A cohort of 1000 
colorectal cancer patients was assessed by immunohistochemistry for 
expression of CD44, c-Myc and tumour stromal content. TMA blocks comprised 
of luminal, central and advancing edge cores were used to account for tumour 
heterogeneity. High nuclear c-Myc expression in tumour epithelial cells was 
associated with poor 5 year survival (p <0.001). Surprisingly, it was also 
associated with a lack of metastasis and low tumour stage. In contrast to 
previous studies, membranous CD44 expression was associated with low 
primary tumour stage (p 0.001) and metastasis (p 0.003). Cytoplasmic CD44 
staining was observed to follow two distinctive patterns, perhaps representing 
different variants. CD44 and c-Myc expression in the stroma were localised to 
lymphocytes and plasma cells, respectively. Both were associated with positive 
clinical outcomes, including low primary tumour stage and 5 year survival, 
consistent with previous studies regarding immune infiltration. Increased 
tumour stroma content was associated with worse outcomes, consistent with 
the “mesenchymal” consensus molecular subtype 4. CD44 expression and 
tumour stroma content were significantly correlated, supporting the role of 
CD44 in epithelial to mesenchymal transition. This study presented an 
opportunity to better understand the expression of c-Myc, CD44 and the 




• Positive nuclear c-Myc expression was associated with poor 
survival 
• MLH1 deficiency led to increased c-Myc expression 
• Stromal c-Myc expression was associated with improved survival 
• High CD44 expression was associated with good clinical outcomes 
• Stromal CD44 expression was associated with poor survival 
• c-Myc+/CD44+ patients showed positive clinical outcomes 
• Low stromal content was associated with high CD44 expression 
• High stromal content was associated with poor outcome 
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Introduction 
Colorectal cancer pathology  
Colorectal cancer (CRC) is the third most common cancer in men and women, 
and the fourth most common cancer in the UK overall [1]. 44% of patients 
diagnosed with colorectal cancer die from the disease, and 10 year survival is 
57%, with recurrence in 30% of patients [2]. Of those diagnosed with colorectal 
cancer, more than 95% of patients have adenocarcinoma, which originates in 
glandular cells within the colon or rectum. 75% are diagnosed at a local stage 
(I and II). Stage I tumours invade as far as the muscularis propria within the 
colon, and can usually be treated with surgery alone (85-95% of cases). Stage II 
tumours may infiltrate beyond the colon wall into adjacent organs, but not into 
the lymph nodes. Depending on the extent of invasion, 5 year overall survival 
rates can vary between 58-87%, and patients may be treated with surgery and 
fluorouracil (5FU)/leucovorin combination, although there is some debate as 
to the usefulness of chemotherapy at an early stage, when surgery alone has a 
reasonable success rate. Stage III tumours show some level of metastasis to the 
lymph nodes, and surgery and radiotherapy with adjuvant treatment has been 
recommended for these patients. This includes the use of fluoropyrimidine 
based chemotherapy (typically 5FU) in conjunction with oxaliplatin or targeted 
agents such as cetuximab [2]. 
The progression of normal colon into adenoma and eventually into an invasive 
adenocarcinoma occurs following a series of genetic and epigenetic changes. 
The three key pathways this follows in colorectal cancer are chromosomal 
instability (CIN), microsatellite instability (MSI), and CpG island methylator 
phenotype (CIMP). Chromosomal instability occurs in up to 70% of sporadic 
colorectal cancers, making it the most common pathway of genomic change. It 
leads to karyotypic changes in the cells, including loss of heterozygosity and 
aneuploidy [3]. The most common “canonical” sequence of changes was first 
described by Fearon and Vogelstein in 1990 [4] and has been expanded on over 
the last 30 years to show the genes and pathways involved (see figure 1). The 
initial change occurs when the APC tumour suppressor gene is mutated, 
typically by frameshift or nonsense mutation, leaving a truncated protein. APC 
usually blocks transition from G1 to S phase in the cell cycle, and disrupting this 
allows replication to progress unchecked. As APC regulates β-catenin, these 
mutations lead to constitutive overexpression of β-catenin and prolonged 
activation of the Wnt signalling pathway, important in determining cell fate and 
motility [5]. Mutations in β-catenin or hypermethylation of the APC promoter 
can also lead to this. The next canonical alteration occurs in KRAS [6] which is 
mutated in up to 50% of cases of colorectal cancer [7], typically at codon G12. 
After these mutations occur, loss of heterozygosity (LOH) at 18q is often 
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observed, particularly at 18q21, especially in advanced colorectal cancer. For 
loss of heterozygosity to occur, a minimum of one allele of a gene must be lost 
and the other is often mutated rendering it non-functional. One of the genes 
that is commonly lost in this step is DCC (Deleted in Colorectal Carcinoma), a 
tumour suppressor gene that is missing in approximately 70% of colorectal 
cancers, whose loss is negatively associated with survival [6]. However, DCC is 
rarely mutated and it is now considered that allelic loss of SMAD2 or SMAD4 is 
probably the more important target of LOH at 18q [8]. Mutations in PIK3CA 
occur late in the adenoma-carcinoma sequence. The final mutation that is 
associated with the adenoma-carcinoma progression is of TP53. The p53 
protein is involved in the control of the cell cycle and apoptosis, inducing arrest 
of the cell cycle between G1 and S phase to facilitate DNA repair prior to 
replication. The mutation is thought to occur at the time of transformation 
from an adenoma to a carcinoma. 
 
Figure 1: The adenoma-carcinoma sequence first described by Fearon and Vogelstein. An increase in 
mutations in APC, KRAS, TP53 and PIK3CA are accompanied by loss of heterozygosity at 18q. Tumour 
progression is associated with these changes. This image is taken from Pino et al, 2010 [3]. 
Up to 20% of colorectal cancers show an aberrant pattern of methylation 
associated with clinical outcomes. This subset of CRC is controversially 
described as molecularly distinct from other groups, including CIN, and is 
termed the “CpG island methylator phenotype” [9]. CIMP status can be 
determined by assessing the methylation of the promoter regions of the genes 
CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1. 
Patients with 5 or more of these promoters methylated are classified as CIMP 
positive [10]. CIMP tumours are associated with proximal colon disease and 
poor differentiation, much like MSI tumours.  
Tumours with microsatellite instability account for roughly 15% of sporadic 
colorectal cancer. Microsatellite instability was first observed by Ionov et al in 
1993, where they described the slippage of regions of the genome with tandem 
repeat sequences as an early event in colorectal cancer [11]. MSI tumours tend 
to carry more mutations than CIN tumours due to a failure to repair errors 
made by DNA polymerase during replication. MSI occurs in more than 95% of 
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patients with Lynch syndrome, a familial form of colorectal cancer that occurs 
due to faults in the mismatch repair genes. Tumours with microsatellite 
instability tend to be more frequent in female patients, the proximal colon, and 
may have mucinous histology [6]. They are often associated with a different 
mutation profile to that of tumour with CIN. There is a very strong association 
with genome wide hypermethylation and BRAF mutations (which can be seen 
in up to 60% of sporadic tumours with MSI). In addition, there are mutations 
within genes which contain repeat sequences in coding regions such as TGFBR2 
and BAX [12, 13]. 
Inherited colorectal cancer 
The vast majority of CRCs arise as sporadic tumours although it is thought that, 
even in these, there is a genetic contribution of 15% of risk [14]. There are 
however a number of family cancer syndromes in which germline mutations 
are associated with a high risk of CRC. 
Lynch syndrome, associated with the MSI changes described above, is the most 
common familial syndrome associated with colorectal cancer and accounts for 
3% of new cases. It is also associated with other cancers, the most frequent of 
which is endometrial cancer. Like spontaneous MSI tumours, phenotypically it 
is connected with cancer in the proximal colon, and is often poorly 
differentiated or mucinous. It is caused by germline deficiency in the mismatch 
repair (MMR) genes MLH1, MSH2, MSH6 or PSM2, or by deletion of EPCAM, 
which causes inactivation of MSH2. Colorectal cancer develops more rapidly in 
patients with Lynch syndrome due to the more frequent presence of polyps 
within the colon and poor mismatch repair ability [15]. As a result of this, 
patients under the age of 50 diagnosed with colorectal cancer are tested for 
Lynch syndrome. Testing for Lynch syndrome is performed by either 
immunohistochemistry (IHC), for loss of MMR protein expression or PCR, for 
the presence of MSI. Patients with MMR deficiency do not respond to 
treatment with 5FU [16], as they are insensitive to the mode of action used, 
but are more sensitive than MMR competent patients to drugs such as FOLFOX, 
a combination of folinic acid, fluorouracil and oxaliplatin [17].  
Other inherited syndromes leading to colorectal cancer include Familial 
Adenomatous Polyposis (FAP), attenuated FAP, and Turcot syndrome [6]. FAP 
is a rare disease that affects less than 1 in 10,000 people, but those diagnosed 
with it have an almost 100% risk of colorectal cancer by the age of 50. It is 
characterised by the formation of hundreds of adenomatous polyps in the 
colon at a young age, and is treated with colectomy and regular follow ups to 
reduce the risk of cancer. Familial adenomatous polyposis is caused by 
inherited mutations in the APC gene, one of the earlier mutations to occur in 
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the Vogelstein model of colorectal carcinoma, which is why the cancer occurs 
in young patients [18]. 
The consensus molecular subtype (CMS) classification of CRC 
Multiple groups have tried to categorise colorectal cancer into groups [19] [20] 
[21] [22] [23] [24] [25], in addition to characterisation by CIN, MSI or CIMP. The 
main subtyping that is currently observed is the system proposed by Guinney 
et al in 2015. They combined the data from 18 cohorts, normalised to reduce 
technical variation, and looked at the data using the subtyping of 6 different 
groups. They primarily focussed on transcriptomic data but also used 
proteomics, copy number variation and methylation data. They produced a 
system that split colorectal cancers into one of four molecular subtypes (CMS1-
4) [26]. CMS1 consists of an “MSI immune” type, including most MSI and CIMP 
high tumours, characterised by widespread hypermethylation and a high 
frequency of BRAF mutations. Like other MSI tumours, these are associated 
with right-sided lesions and are more common in females. They also showed 
expression of genes associated with immune infiltration. CMS2 is the 
“canonical” subtype, with high chromosomal instability, loss of tumour 
suppressor genes and gain in oncogenes. These tumours are associated with 
left-sided lesions and upregulation of the Wnt and MYC pathways, and have 
the best survival after relapse. The third molecular subtype is CMS3, 
“metabolic”. This subtype is associated with fewer somatic copy number 
alterations (SCNAs) and a high prevalence of CpG island phenotype. There is a 
high frequency of KRAS mutations and they are enriched for metabolic 
pathways. It shares similarities with the “metabolic” subtype described in 
gastric cancer, hence the name [27]. CMS4 is the “mesenchymal” subtype, 
which shows an upregulation of genes associated with the epithelial to 
mesenchymal transition (EMT). Epithelial to mesenchymal transition is 
important in altering the CRC cells from an organised epithelial type to a more 
mesenchymal type, allowing easier cell motility, leading to metastasis [28]. 
There is a high level of stromal infiltration and an overexpression of 
extracellular matrix proteins, and it is the group associated with the most 
advanced stages of diagnosis and the worst overall survival [26].  
c-Myc 
The MYC family of helix-loop-helix leucine zipper proteins consists of c-Myc, n-
Myc and l-Myc, which are involved in multiple cellular functions, including cell 
growth, proliferation, metabolism and more [29]. c-Myc is the best 
characterised of these proteins, and is thought to regulate approximately 15% 
of genes. The oncogenic function of c-Myc was first demonstrated in its role in 
Burkitt’s lymphoma in 1982. c-Myc is found on human chromosome 8q24, and 
in Burkitt’s lymphoma is translocated into the immunoglobulin µ chain gene 
[30]. The sequence of the c-Myc gene was determined along with its structure 
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in 1983. It contains three exons and two introns, and is located on chromosome 
8q24 [31]. This gene produces a 65 kDa, 439 amino acid phosphoprotein that 
is typically expressed in the nucleus [29].  
c-Myc usually acts in a heterodimer with the bHLH zipper protein, MAX, to 
perform its cellular functions. The heterodimerisation of c-Myc and MAX allows 
them to recognise Enhancer-boxes (E-boxes) on their targets, which c-Myc 
alone would not have the affinity for [32]. The canonical sequence of E-boxes 
is CACGTG, and is recognisable by c-Myc-MAX, although some non-E-box 
sequences can be recognised when c-Myc-MAX are at high concentrations, and 
this may be involved in the oncogenic overexpression of c-Myc targets [33]. 
These interactions are supported by the c-Myc binding protein TRRAP, to 
upregulate gene expression and recruit histone acetyltransferases. MAX is also 
able to dimerise with the MAD protein, forming the MAD-MAX complex, 
competing with c-Myc-MAX in order to repress transcription [34]. In addition 
to c-Myc and MAD, MAX can bind MNT and MGA proteins to control 
transcription in a contextual manner [32].  
c-Myc expression is associated with many different cellular processes (figure 
2), including the opposing functions of proliferation and apoptosis. It has been 
theorised that this may depend on a threshold of expression, where it switches 
from a proliferative function to an apoptotic one. Or, it may be dependent on 
its interaction with other molecules [35]. c-Myc is one of the most frequently 
amplified oncogenes seen in many different human cancers including CRC. In 
addition, in colorectal cancer it is stimulated by the dysregulation of the Wnt 
signalling pathway. Loss of functional APC occurs in more than 75% of CRC 
patients [36], resulting in unchecked expression of β-catenin and Wnt 
signalling. The accumulation of β-catenin leads to activation of the TCF/LEF 
family of transcription factors, which are responsible for the activation of c-Myc 
[37]. c-Myc is rarely mutated in CRC, and instead overexpression is induced by 
β-catenin and TCF4 in colorectal tumours [38]. The relationship between c-
Myc, LEF1 and nuclear β-catenin has been theorised to be important to 
maintain the prolific state of colorectal cancer cells [39]. The role of c-Myc in 
the Wnt signalling pathway is also connected to its purpose in maintaining a 
stem-state [40]. The polycomb protein BMI1 activates Wnt signalling, leading 
to upregulation of c-Myc. In turn, c-Myc binds to the E-box in BMI1, initiating a 
positive feedback loop of the Wnt signalling pathway [41]. 
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Figure 2: Pathways c-Myc is involved in in colorectal cancer. c-Myc plays a role in regulating approximately 
15% of genes, in a multitude of pathways, some of which are shown here.  
c-Myc in stem cell biology 
c-Myc expression is tightly regulated in normal tissues, but its functions in 
embryonic stem cells are such that loss of c-Myc leads to embryonic lethality. 
This is brought about by early differentiation into progenitor-like cells, via 
proteins such as Oct4 and Nanog. The reliance of c-Myc on MAX to enable 
binding to its targets means that when MAX is lost, the undifferentiated state 
of cells is also lost. Levels of Sox2, Nanog and Oct3/4 gradually decrease when 
MAX is lost, driven by the upregulation of the MAPK pathway, whereas 
differentiation markers of endoderm, ectoderm and trophoderm, such as 
Gata6, Sox17, Nestin and Cdx2, are upregulated [42]. When the first induced 
pluripotent stem cells (iPSCs) were produced, c-Myc, along with Oct3/4, Klf4 
and SOX2, was essential in inducing and maintaining the dedifferentiated state 
of the cells [43]. Chimeric mice from these iPSCs are prone to an increased risk 
of tumour formation, owing partly to the reactivation of c-Myc. Omitting c-Myc 
from the iPSC protocols reduces the efficiency of their generation, but greatly 
reduces the risk of tumourigenesis. It has been observed that l-Myc can be used 
to replace c-Myc in order to produce human iPSCs without increasing the risk 
of tumourigenesis [44].  
The role of c-Myc in colorectal cancer cell metabolism was demonstrated by 
Satoh et al in 2017, in the correlation between c-Myc expression and more than 
230 genes involved in metabolism. Many of these genes were upregulated, and 
involved in such pathways as purine/pyrimidine synthesis, glycolysis and the 
Page 10 of 89 
 
MAPK pathway. Pathways that were downregulated in conjunction with 
decreased c-Myc expression included fatty acid oxidation and the citric acid 
cycle. The role of c-Myc in glycolysis suggests that it is a key player in producing 
the Warburg effect, where glucose metabolism is increased and fermented to 
lactate. When c-Myc was knocked out, the expression of many of the genes 
identified returned to normal. The role of c-Myc as a key regulator of metabolic 
reprogramming in CRC suggests that it has potential as a therapeutic target 
[45]. 
c-Myc has a role in the adaptation of cancer stem cells to a hypoxic 
environment, mediated by the Warburg effect [46]. PKM2 is an important 
driver of glycolysis, and plays an important role in the Warburg effect. Its 
expression is upregulated by c-Myc in cancer stem cells, and it activates 
hypoxia inducible factor 1 (HIF1) in a positive feedback loop. c-Myc also 
promotes glycolysis via glucose transporter type 1 (GLUT1), and pyruvate 
dehydrogenase kinase 1 (PDK1). The intracellular form of CD44 suppresses 
PKM2, promoting glycolysis and increasing the activity of the pentose 
phosphate pathway [46]. Triple negative breast cancer is heavily dependent on 
glutamine metabolism, mediated by amino acid transporters such as 
xCT/SLC7A11. The transmembrane glycoprotein CD44v stabilises this 
transporter in the cell membrane of cancer stem cells. CD44v increases the 
concentration of intracellular cysteine, aiding in the production of glutathione 
(GSH). GSH is involved in the elimination of reactive oxygen species, preventing 
apoptosis or differentiation of cancer stem cells [47]. The role of CD44 in 
colorectal cancer will be discussed further later in this thesis.  
The role of c-Myc in colorectal cancer 
c-Myc expression is associated with the canonical (CMS2) process of colorectal 
cancer development and better survival outcomes, including after relapse [26]. 
Overexpression of MYC mRNA is seen at all stages of CRC, from adenoma 
development to metastasis [38]. c-Myc has been observed to be linked to 
mismatch repair (MMR). In a study by Partlin et al, they demonstrated that c-
Myc and MAX bind to MLH1 and MSH2 both in vivo and in vitro [48]. They used 
coprecipitation to show that c-Myc is found when MLH1 and MSH2 are pulled 
down. In another study by Bindra et al, 2007, they discuss whether hypoxia is 
a controlling factor in mismatch repair. They initially suggest that hypoxia led 
to the downregulation of MLH1 and MSH2, as the protein HIF1α displaces c-
Myc from its binding site in a MAD-MAX like fashion. However, they then 
discussed the possibility that the downregulation of MLH1 and MSH2 occurs 
independent of HIF-1α expression, and relies only on the interaction of c-Myc 
and other MAX-associated proteins [49]. They also found that c-Myc was down-
regulated under hypoxic conditions. c-Myc has been related to epithelial to 
mesenchymal transition (EMT), where it enhances SNAIL expression [50]. EMT 
is involved in the development of metastasis, leading to cancer progression and 
poor prognosis [51].  
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Given the role of overexpressed c-Myc in colorectal cancer, it would seem a 
good choice for therapeutic targeting. In the past scientists were reluctant to 
target c-Myc directly, due to the large number of genes under its transcriptional 
regulation, including in normal tissues, and the homology to its family members 
[52]. Direct inhibitors of c-Myc such as Omomyc [53], which binds to c-Myc 
binding sites and to MAX, and bromodomain and extraterminal domain 
inhibitors (BETi) [54], which bind the c-Myc super enhancer and repress it, are 
examples of strategies that could prevent the oncogenic expression of c-Myc 
and stop the proliferation of tumour cells.  
CD44 
CD44 (also known as Hermes, PGP1, Indian blood group and HCAM) is a 
transmembrane glycoprotein associated with colorectal cancer. It has multiple 
variants due to alternate splicing, the most common of which is the standard 
form CD44s. The other variants are denoted by CD44v. These different variants 
are associated with different cell types and disease phenotypes. The main 
ligand of CD44 is hyaluronic acid (HA) which is an extracellular matrix protein.  
CD44 is found on chromosome 11p13 and has 20 exons. Alternative splicing of 
these exons in the pre-mRNA occurs to produce multiple isoforms. CD44s, the 
standard form of CD44, is found in lymphocytes and fibroblasts, and can also 
be known as CD44h (haematopoietic CD44). The structure of CD44 proteins can 
be seen in figure 3. It consists of an N-terminal domain at exons 1-5, which 
binds to the extracellular matrix via proteins such as hyaluronic acid (HA), its 
main ligand, and others such as fibronectin and laminin. There is then a stalk 
shaped structure which may be elongated to include the variable exons in 
CD44v proteins. At the C-terminal of the protein are a transmembrane region, 
associated with lipid raft binding, and a cytoplasmic tail [55]. This cytoplasmic 
tail contains important intracellular signalling motifs and mediates the 
interactions with the cytoskeleton. CD44 is commonly found at the basolateral 
end of polarised epithelial cells and on the leading edge of migrating cells.  
Alternative splicing and post-translational modification are key factors in 
producing CD44 proteins with distinctive functions. CD44s occurs when the 
variable exons are spliced out, leaving exons 1-5 and 16-20 (excluding exon 18) 
to form an 85 kDa protein [56]. Alternate forms of CD44 include CD44v6, 
commonly associated with colorectal cancer, CD44v3, seen in cancer stem cells 
in head and neck cancers, and CD44v8-10, associated with gastric cancer [57]. 
CD44 is prone to both N and O glycosylation [58], with O glycosylation in 
particular being associated with CRC. The addition of these glycosylate groups, 
as well as other post-translational modifications such as phosphorylation, 
contributes to the wide range of functions and high molecular weight of CD44 
[56]. Aberrant O-glycosylation of CD44 is associated with dysregulated 
expression and delivery, and a higher expression of CD44 being observed in 
exosomes [59]. 
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Figure 3: The structure and subcellular location of CD44. A shows the key domains in CD44, the amino 
terminal domain, the variable domain which consists of 10 exons that undergo alternate splicing to 
produce multiple proteins, the transmembrane and cytoplasmic domains. Key isoforms of CD44 in CRC 
include the common form of CD44 is CD44s, an epithelial form (CD44e), and CD44v6, which is associated 
with poor prognosis in adenocarcinoma. B shows the CD44 protein anchored into the cell membrane. The 
extracellular domains interact with HA, OPN and MET, whereas the intracellular domains interact with 
ERM and ankyrin. CD44 may undergo proteolytic cleavage by ADAM10, ADAM17 and MT1-MMP to 
release the extracellular or intracellular parts of the proteins into their environments. 
CD44 is expressed in multiple cell types, including epithelial, lymphocytic, 
granulocytes and neuronal cells [60]. The main ligand of CD44, hyaluronic acid, 
is a key component of the extracellular matrix (ECM). HA is a glycosaminoglycan 
(GAG) protein, which functions as a structural protein and plays a role in wound 
healing and inflammation, cell motility and proliferation [61]. The interaction 
of CD44 with HA is reflective of its involvement in cell motility, and may be 
conducive of cells moving through the extracellular matrix [55]. The N-terminal 
domain of CD44 contains other protein-binding domains that have led to the 
conclusion that CD44 binds other proteins in the ECM, including other GAG 
proteins, growth factors, cytokines and matrix metalloproteinases, although 
this has yet to be confirmed [60].  
Intracellular functions of CD44 
In addition to the interactions with hyaluronic acid and the extracellular matrix, 
CD44 may play a role in extravasation, by binding to E-selectin. It has been 
demonstrated that both CD44s and CD44v isoforms can mediate this 
interaction, on hematopoietic cells and colon cancer cells respectively [62]. 
Cellular migration of both leukocytes and cancer cells can be mediated by 
CD44-HA interaction. One important mechanism that allows this to occur is the 
proteolytic cleavage of CD44 by metalloproteinases as seen in figure 3. 
Okamoto et al (1999) have shown that this cleavage differs in mode of action 
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between leukocytes and cancer cells, but occurs in the same location 
regardless of CD44 isoform, and the difference is most likely due to post-
translational modifications. They found a 25 kDa protein that specifically 
reacted to their CD44cyto antibody but not their CD44ecto antibody. The 
expression of this protein was also increased in those cell lines that had a higher 
level of soluble CD44 in the supernatant [63]. In a later publication, they 
demonstrated the importance of cleavage in multiple tumour types, including 
colorectal carcinomas. They found that 90% of colon carcinoma tumours 
showed cleavage of CD44, where their matched normal partners did not [64].  
CD44 is subject to proteolytic cleavage, and therefore can exist in three forms, 
a full-length, membrane bound protein, a soluble extracellular cleavage 
product and an intracellular fragment (CD44ICD). Ectodomain cleavage of CD44 
is stimulated by membrane-associated matrix metalloproteinases and Ras 
proteins. CD44 ectodomain cleavage is dependent on ADAM10 Ca2+ stimulation 
or ADAM17 activation by Rac, and is associated with detachment from the 
ECM. Another metalloproteinase associated with CD44 ectodomain cleavage is 
MT1-MMP. This protein is expressed in many tumour types and is localised to 
the leading edge of the cell in the lamellipodia. Further cleavage of CD44 occurs 
and depends, as in many other type I transmembrane proteins, on γ-secretase. 
This releases the CD44 intracellular domain (ICD), which can migrate to the 
nucleus and activate gene transcription [65].  
The cytoplasmic domains of CD44 contain residues for binding to intracellular 
proteins. These include ezrin/radixin/moesin (ERM) proteins and ankyrin. The 
ERM proteins bind to long actin filaments, and ankyrin binds to the protein 
spectrin. The network of ankyrin, spectrin and other accessory proteins and 
short actin oligomers is thought to play a role in protein and lipid assembly for 
signalling and other intracellular functions. These interactions are not thought 
to play a part in the cell adhesion function of CD44, but may be important with 
regards to hyaluronic acid signalling [66]. The binding site of ankyrin (amino 
acids 304-318) is downstream of the ERM binding site (amino acids 292-300), 
and binding of these proteins is phosphorylation dependent via Rho A and PKC, 
respectively [55]. Ankyrin and ERM proteins facilitate clustering of CD44 within 
the cell membrane to optimise E-selectin interaction, important in cell rolling 
[66].  
CD44 in the colon and colorectal cancer 
Three CD44 isoforms are commonly studied in the gut epithelium. CD44s is the 
most commonly expressed isoform, found in lymphocytes and fibroblasts, in 
addition to epithelial cells and in colorectal cancer. It consists of the first five 
exons and the final five exons. CD44v6 and CD44v4-10 are also commonly 
expressed in the colon epithelium [67]. CD44v4-10 is highly expressed in colon 
stem cells, and is involved in the initiation of adenoma. CD44v is also associated 
with familial adenomatous polyposis in mouse models [68]. Given its 
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subcellular location and involvement in metastasis, it has been suggested that 
CD44 is under the influence of the Wnt signalling pathway. Wnt signalling is 
often upregulated in CRC, which may account for the high levels of CD44 seen 
in patients [67]. This pathway is important in epithelial to mesenchymal 
transition (EMT), as demonstrated by the increase of β-catenin in poorly 
differentiated tumour cells and cancer stem cells [69]. CD44 is described as 
being a marker of stem cells both in normal and in malignant colon [70]. Along 
with Lgr5 and EpCAM, it has been used to identify a CSC population that is 
responsible for increased EMT [71]. CD44 isoform switching has also been 
implicated in EMT. Studies have shown that CD44s is associated with 
mesenchymal-like cells, and CD44v associated with epithelial-like cells [72].  
CD44v6 is a particularly important isoform in CRC. It is known to be associated 
with metastasis and poor outcome of patients, and binds to hepatocyte growth 
factor receptor (MET) in the presence of hepatocyte growth factor (HGF) and 
osteopontin (OPN) produced in the tumour microenvironment [73]. OPN is 
involved in multiple biological processes including bone formation, 
inflammation, immune response and tumourigenesis. CD44v6 specifically has 
an OPN binding domain that allows the two proteins to interact, mediating 
metastasis. It exhibits pro-metastatic effects on tumours by enabling tumour 
cells to disseminate via hypoxia-induced angiogenesis and extracellular matrix 
remodelling. In addition, tissues which physiologically produce OPN may be 
targets for tumour homing, such as the bone or liver [74]. In a study by Todaro 
et al, they demonstrated that CD44v6 positive cancer stem cells led to a more 
aggressive and invasive phenotype both in vivo and in vitro. Expression of 
CD44v6 was increased in response to HGF, OPN and SDF-1 exposure, leading to 
enhanced migration and metastasis. These cells also showed constitutive 
activation of the PI3K/AKT pathway, and confirmed that CD44v6 expression 
correlates with Wnt/β-catenin pathway activation [73].  
CD44v6 clinical effect 
In many cancers, a high percentage of CD44v6 positive cells is indicative of a 
poor clinical outcome, likely due to the association with increased metastatic 
potential. CD44v6 overexpression has been shown to be related to stage and 
lymph node metastasis, as well as distant metastasis, and is particularly 
associated with lung and liver metastasis [67, 75]. The interaction with OPN 
may facilitate this, as described above. It has been suggested that p53 exhibits 
an inhibitor function on CD44, and that mutation of p53, common to CRC, 
allows the anti-apoptotic and proliferative activities of CD44v6 to run 
unchecked [76]. CD44v6 shows a stronger affinity for HA than CD44s, which is 
important for chemoresistance. Their interaction stimulates PI3K/Akt 
activation, which stimulates the production of P-glycoprotein, which allows the 
tumour cells to pump toxins, including therapeutic agents, out and into the 
lumen [77].  
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Project overview 
The aims of this project are to understand the importance of two biomarkers, 
c-Myc and CD44, in colorectal cancer. 1000 patients provided tumour samples 
from locations including luminal, central, advancing edge and normal colon. 
These samples were then stained immunohistochemically with c-Myc and 
CD44 antibodies, and the slides scanned. Those images were provided for 
histopathological analysis. Upon completion of the histological analysis, the 
two biomarkers were subjected to statistical analysis alongside the clinical 
data, to determine if c-Myc or CD44 may have prognostic value. Tumour stroma 
content was similarly assessed to determine if it impacted clinical outcomes. 
Finally, bioinformatic analysis was performed using the Cancer Genome Atas 
(TCGA) colorectal cancer data, to analyse the pathways and processes that 
these biomarkers are involved in.  
Methods 
Patient cohort 
This study was performed on a Tissue MicroArray created from a cohort of 1000 
sequential patients treated for CRC at the Nottingham University Hospitals 
between 2008 and 2014. Specimens were obtained from colorectal cancer 
tissues and normal colonic mucosa and the following data about the patients 
were retrieved: sex, age at diagnosis, survival data, cause of death, tumour site, 
tumour size, lymph node involvement, metastases, final stage, dukes, stage, 
grade, recurrence, vascular invasion, perineural invasion, lymphovascular 
invasion, peritumoral lymphocytes, tumour edge, tumour budding, 
MLH1/PMS2/MSH2/MSH6 expression and MMR status. The creation of the 
TMA and the retrieval of the clinic-pathological data was undertaken by a 
senior research assistant in the lab. 
Histopathology methods 
Materials 
Table 1: Materials used in IHC analysis 
Item Supplier Catalogue number 
Tissue Microarrayer Beecher Instruments MTA-1 
X-tra Slides Leica Biosystems 3800050 
Monoclonal Mouse Anti-




Myc antibody clone Y69 
Concentration 1:20 
Abcam Ab32072 
Benchmark ULTRA IHC/ISH 
System 
Roche  N750-BMKU-FS05342716001 
Pannoramic Slide Scanner 3DHistech - 
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Methods 
Colorectal cancer Tissue MicroArray (TMA) blocks were prepared according to 
standard procedures as previously described [78]. Formalin fixed, paraffin 
embedded (FFPE) tissue blocks and their corresponding haematoxylin and 
eosin (H&E) slides were retrieved. Regions of interested were annotated on the 
H&E slides by a pathologist, to identify the areas to be cored. Tissue cores with 
a diameter of 0.6 mm were extracted from the original block and transferred 
to a recipient block by a Tissue Microarrayer (Beecher Instruments, US). Four 
cores were taken from 1000 colorectal cancer samples including three from the 
tumour (luminal, central and advancing edge) and one from the normal 
adjacent area, and split across 15 TMAs with controls. Three regions from the 
tumour were taken, to allow interrogation of intratumoural heterogeneity, 
common in colorectal cancer [79]. TMA blocks were cut at a thickness of 4 µm 
and mounted on slides (Surgipath X-tra Adhesive, Leica, Germany). These slides 
were then stained with CD44 (Agilent, US) and c-Myc (Abcam, UK) antibodies 
on a Benchmark Ultra (Roche, US) and imaged with a 3D Histech slide scanner 
producing .mxrs format files. Images were analysed in QuPath v0.2.0-m11. 
Immunostaining was undertaken by the Histopathology department of the 
Queen’s Medical Centre using standard techniques. Scanning was performed 
at X20 magnification. 
Image analysis 
QuPath Set up 
QuPath-0.2.0-m11 [80] was used to open and analyse the TMA images. This is 
a free software which allows the user to perform manual or automated scoring 
of tissue samples. In this case only manual analyses were done, due to the 
nature of the antigens targeted; their presence in multiple cellular 
compartments meant scoring by eye minimised conflicting results. The process 
for creating a project (to save all images from one biomarker into one analysis 
file) and opening images was performed using commands within the 
application as follows: 
Create new project > Select Folder > Add images > Choose files > Set image type 
> Rotate image > Import 
Images were rotated 180° (see command above) as the majority of TMAs were 
originally displayed upside down. Cores were labelled with a column label (1-
12) and a row label (A-Z) to facilitate accurate analysis and identification of the 
cores of interest within the slide. Core size was set to 0.75 mm for all TMA slide 
images. TMA segregation was performed using the following commands: 
TMA > TMA dearrayer > TMA core diameter (0.75mm) > Column labels (1-12) 
> Row labels (A-Z) > Run  
Labelling the TMAs in this way gave the advantage that the cores could be 
annotated for core presence/absence by selecting the cores by double clicking 
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until highlighted yellow, right clicking and selecting “Set core valid” to mark the 
core for analysis or “set core missing” to mark the core as missing or 
nonscorable. Where the software had not recognised the correct positioning 
of cores (for example due to faint staining), the TMA selection boxes could be 
moved to the correct location by double-clicking and dragging the box to the 
desired location. This allowed easier visualisation of the cores within the image. 
In addition, some cores were larger than the boxes (figure 4f), and placing the 
boxes over the cores meant that the same sized region was used for all 
analyses. To reduce bias from this process, the boxes were placed in the middle 
of the cores (where possible) and that area was then scored. 
Exclusion criteria 
Cores were excluded as seen in figure 4 if: 
• Cores were absent (figure 4 H) 
• Cores were rendered nonscorable by: 
o Folding or tissue lifting leading to insufficient epithelial content 
(figure 4 A & E) 
o Out of focus (blurry) images (figure 4 G) 
o Cores overlapped/were too close together to be discernible  
o Cores were jumbled and unassignable (figure 4 F) 
o Epithelial content was less than 15% (figure 4 B) 
o Unexpected tissue type was present e.g. normal colon present 
where cancer was expected and vice versa (figure 4 C & D) 
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Figure 4: Exclusion criteria for QuPath image analysis. Cores were excluded for a number of different 
reasons including folding (A), insufficient epithelial content (B), incorrect epithelial type i.e. presence of 
normal colon (C) where tumour is expected or presence of tumour (D) where normal colon is expected. 
Other reasons for exclusion included tissue lifting (E), cores being unassignable (F), out of focus images 
(G), or lack of tissue (H).  
Histoscore calculation 
The histoscore (H-score) is a widely used method of assessment of 
immunostaining which allows heterogeneity of staining to be incorporated into 
the final score. The method usually depends on identifying 4 bands of intensity 
staining i.e. 0 = no staining, 1=weak staining, 2 = moderate staining, 3 = strong 
staining. The percentage of cells in each band is multiplied by the value of the 
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band. The histoscores (H-score) for each region of interest were calculated as 
follows: 
Histoscore = (0 x (%0 cells)) + (1 x (% 1+ cells)) + (2 x (% 2+ cells)) + (3 x (% 3+ 
cells))  
This methodology allows for a minimum score of 0 and a maximum score of 
300. For this study, in the case of CD44 cytoplasmic staining, there was a 
maximum score of 200, because the staining was consistently low intensity. 
Histoscores for every core in the tumour regions of luminal tumour, central 
tumour and advancing edge tumour were calculated and averaged to account 
for intratumoural heterogeneity. The H-scores of each tumour core were 
averaged assuming they met the analysis criteria described above. The H-score 
of the normal tissue was kept separate for comparison. H-scores for each 
cellular compartment (i.e. nuclear, cytoplasmic, membranous) and for stroma 
were generated individually. Examples of typical staining for each biomarker 
can be seen in figure 5. Cytoplasmic scoring for c-Myc was assessed as 
percentage positive cells as the staining was homogeneous between samples. 
CD44 H-score assessment 
CD44 staining was assessed for the following conditions: 
• Cytoplasmic staining: scored from 0-2 
• Membrane staining: scored from 0-3 
• Nuclear staining: scored from 0-3 
• Stroma staining: scored from 0-3 
c-Myc H-score assessment 
c-Myc staining was assessed in the following conditions: 
• Nuclear staining: scored from 0-3 
• Cytoplasmic staining: percentage positive cells 
• Stromal staining: scored from 0-3 
Epithelial content assessment: 
The epithelial content of each tumour region was assessed prior to biomarker 
analysis. This was necessary to determine if the cores were suitable for 
biomarker analysis, and allowed the assessment of tumour epithelial content 
with clinical outcomes. In addition, it gave an opportunity to compare the two 
sets of slides, as epithelial content may vary from section to section as the 
tumour changes. 
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Figure 5: Examples of expression of c-Myc (A-F) and CD44 (G-O) in colorectal carcinoma (A-L) and normal 
colon (M-O). c-Myc: Negative epithelial staining can be seen in A. Cytoplasmic staining in c-Myc (B) was 
scored for percentage of positive cells. Plasma cells were positive for c-Myc as seen in the stroma of C. D-
F show nuclear c-Myc staining varying from 1 (low intensity) to 3 (high intensity). CD44: G shows a tumour 
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sample with no epithelial CD44 staining. Cytoplasmic staining of CD44 was represented as a homogenous 
stain (H) or as a granular stain (I). Nuclear staining (M) was rarely observed for CD44. Immune cells in the 
stroma were frequently stained as in J. CD44 membranous staining in tumour samples can be seen in K 
(low intensity 1) and L (high intensity 3), and in normal samples (M, moderate intensity, 2). . Epithelial 
staining in the normal colon showed a stratified pattern of staining for CD44 (N), with the lower part of 
the crypts being positive and the upper parts were negative. CD44 staining was also observed in the 
stroma, particularly in normal samples, as in O. 
Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics v26 licensed 
from the University of Nottingham.  
The H-score is prone to subjective variation, due to each pathologist scoring 
staining slightly differently. H-score reliability was assessed in two ways. First, 
the inter-observer reliability was assessed by an independent pathologist. Dr 
Abhik Mukherjee gave H-scores for several tumours for each biomarker. When 
compared to my scores, these were within 10% of each other. Traditionally, a 
variability in scores of 10% between pathologists is accepted as a high Kappa 
score. To ensure that intra-observer reliability was consistent throughout the 
analysis, the H-scores for a number of tumours were recalculated on another 
day, to calculate the Kappa statistic. For epithelial content and nuclear, 
cytoplasmic and membranous staining (where applicable) in both proteins, 
these were all highly correlated, above 0.8. 
Additional variables were computed from existing variables as presented in 
table 2. This was done using Transform>Recode into different variables. Clinical 
variables were re-coded in order to perform Chi-square analysis, or perform 
analyses that depended on bivariate or categorical variable input.  
 
Table 2: Variables computed from existing variables into categorical variables 
Name Values Cut-off 
Clinical variables 
Agedichotomised 1, young; 2, old Below/above 50 
GradeDichotomized 1, low; 2, high 1&2, 3 
Sitedichotomized 1, Rightside; 2, Leftside Right colon, other and left 
colon, rectum 
c-Myc variables 
NucAvHScoreMedianSplit 0, Below; 1, Above Below/above 54 
NuclearLowestTertile 1, low; 2, high Below/above 26.33 
NuclearHighestTertile 1, low; 2, high Below/above 85.33 
Nuclearpositive 1, negative; 2, positive 0, any other value 
Nuclearalltertiles 1, lower; 2, middle; 3, higher 0>26.33, 26.33>85.33, 
85.33>300 
CytoAvPositiveMedian None Below/above 2 
CytoAvPositiveonly None 0, any other value 
StromalAverageMediansplit 1, below; 2, above Below/above 6.67 
StromalAverageHscorePositiveOnly None 0, any other value 
Name Values Cut-off 
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StromalAverageHScoreLowtertile None Below/above 3.5 
StromalAverageHScoreHightertile None Below/above 10.3 
CombinedNuclMedCyto75th None See c-Myc results 
CD44 variables 
MembraneHScorePositivesonly None 0, any other value 
MeanMembraneHScore75thPerc None Below/above 57.5 
MeanCytoHScoreMedianSplit None Below/above 58.33 
MeanCytoHScoreTertilesSplit None 0<35, 35<80, 80<200 
MeanNuclearHscorePosNeg None 0, any other value 
MeanStromaHScoreMedialSplit None Below/above 47.5 
MeanStromaHScoreTerts None 0<35, 35<60, 60<300 
NuclearAverageHScore None Below/above 12.6 
LumMemHS75th None Below/above 85 
CentralMemHS75th None Below/above 75 
AEMemHS75th None Below/above 75 
Other variables 
AvTumEpiMedian None Below/above 53.33 
AverageStromaMedianSplit None Below/above 47.5 
cMycCD44combined None See “CD44 and c-Myc 
interaction” 
*continuous variables were split into categorical variables using cut-offs in the right-hand column of 
this table to allow analyses that could not be performed using continuous data 
 
In order to assess the distribution of the data, histograms were prepared using 
analyze>frequencies. The mean, median and mode were computed, as were 
the quartile and tertile splits of the data. Distribution of the data was assessed 
by eye, and correlation between the average H-score and individual tumour 
compartments or normal colon was assessed using Spearman’s or Pearson’s 
rank correlation (analyze>correlation>bivariate). The average scores of each 
cellular compartment were also assessed to see if increased expression in one 
compartment led to increased expression in another, using correlation 
analysis. Chi-squared analysis (analyze>descriptive statistics>crosstabs) was 
used, with adjusted residuals, to determine the relationship between the 
clinical variables and biomarker expression. Mann-Whitney U tests were used 
to assess the relationship between the biomarkers and tumour stroma content. 
Kaplan-Meier and Cox regression methods were used to determine the 
association of each biomarker with survival. Kaplan-Meier analysis was 
performed using 3 year survival, 5 year survival and death by colorectal cancer. 
Cox regression analysis was performed using biomarker status, and with 
multivariate analysis to determine if survival was truly associated with 
biomarker expression or if clinical variables were affecting the results.  
Chi-square analysis was repeated for each biomarker with the additional 
splitting of MMR status added, in the most biologically relevant cellular 
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compartments. This allowed for any confounding results from MMR status, 
which influences CRC outcomes, to be accounted for. 
Tumour epithelium content analysis 
In order to achieve the most representative figures to allow comparison of 
tumour epithelium content with the clinical variables, the mean tumour 
epithelium content was calculated in Microsoft Excel as follows: 
((luminal (CD44) x luminal (c-Myc))/2) x ((central (CD44) x central (c-Myc))/2) x 
((advancing edge (CD44) x advancing edge (c-Myc))/2))/3 
Where one value in one region of interest was not available, the value from the 
other slide would be used. Where both values were not available for a tumour 
region of interest, the mean would be calculated from the other regions of 
interest using the following formulae: 
Calculating average from individual region of interest:  
=IF(A2,IF(F2,AVERAGE(A2,F2),A2)IF(F2,F2,"")) 
Calculating average from multiple regions of interest: 
=AVERAGE(K2:M2) 
This prevented unequal weighting of values and gave a tumour epithelium 
content which was most representative of the true overall tumour content. 
Bioinformatic analysis 
The proteins used as biomarkers in this project may be associated with 
different pathways and known pathogenesis. By testing their association with 
other genes in a known dataset (the Cancer Genome Atlas (TCGA)), it should 
enable us to understand more about their roles in colorectal cancer. TCGA CRC 
differential expression data was provided by Nigel Mongan. The base mean 
expression, log2 fold change data, log fold change standard deviations, 
statistic, p values and adjusted p values were provided for 60,488 genes, 
labelled with Ensembl gene IDs. To look for biologically significant changes to 
gene expression, results were filtered for genes with: 
•  More than ±1 log2 fold change (to shown truly biologically relevant 
changes) 
•  p value below 0.05  
• adjusted p value below 0.05  
To interrogate the data for biologically important changes, the Ensembl gene 
IDs were inputted into WebGestalt [81]. Here, the pathways c-Myc and CD44 
are involved in were interrogated in KEGG, Panther and Reactome. Other 
analyses investigating chromosomal locations and gene ontology were alsp 
performed (data not shown).  
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Figure 6: Parameters used to interrogate differentially expressed genes associated with c-Myc or CD44 in 
WebGestalt. Pathways were analysed to understand and confirm which pathways were enriched when 
CD44 and c-Myc were over-expressed. Gene ontology and chromosomal were interrogated to understand 




1000 patients were included in this analysis. The clinical features of these 
patients are described below. Over half (56.8%) were male, and the majority 
were over the age of 50 (93.7%). Site was re-coded into two variables, “left” 
and “right”. Left-sided tumours included “left” and “rectum” tumours, and 
right-sided tumours included “right” and “other” tumours. The location of 
tumours was split almost equally, with 49% of tumours being right-sided. 72.7% 
of patients survived for three years, but less than half (43%) survived to five 
years. 28.7% of patients experienced recurrence, and 11.9% of patients 
experienced metastasis. Most patients were in stage 2 (40.2%) or stage 3 
(31.9%) at the end of the study. A higher primary tumour stage was generally 
observed, with only 7.4% of patients at T1. Lymph node metastasis was present 
in less than half of patients (N0 57%). The majority of patients were 
experiencing grade 2 colorectal cancer (88.6%), meaning the tumours were 
moderately differentiated [82]. The grades were re-coded from 1 (well-
differentiated), 2 (moderately-differentiated) and 3 (poorly-differentiated) to 
(1 & 2) and 3, in order to classify differentiated and undifferentiated tumours 
more plainly. Vascular invasion was more or less equally split between absent 
or present (48.3%), and the presence of perineural invasion (18.3%) and 
intratumoural lymphovascular invasion (28.7%) were observed less often than 
not. Not all tumours were classified for tumour edge, but of those that were, 
39.5% were classified as a “pushing” tumour edge, meaning that the tumour 
grows outward in a uniform pattern, and 36.7% were classified as “infiltrative”, 
meaning that the tumour grows into the surrounding tissue in a diffuse pattern 
[83]. 2.2% of patients could not be classified for mismatch repair status, but 
most patients were proficient (81.8%) and just 16% were deficient.  
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Overall the frequencies of the clinical features match the published data 
showing that there is no bias in the cohort. There was slightly higher occurrence 
of primary tumour T1 disease than may be expected from an historical cohort 
but this is probably because the NHS Bowel Cancer Screening Program was 
introduced over the period of time of this cohort (2008-2014).  
Table 3: Patient stratification 
Clinical Variable Condition Number (%) 
Gender Female 432 (43.2) 
 
Male 568 (56.8) 
3 year Survival Alive 727 (72.7) 
 
Dead 272 (27.2) 
5 year Survival Alive 430 (43) 
 
Dead 570 (57) 
Synchronous metastasis No metastasis 881 (88.1) 
 
With metastasis  119 (11.9) 
Recurrence  No Recurrence 713 (71.3) 
 
Recurrence 287 (28.7) 
Cause of death  Alive 624 (62.4) 
 
CRC 178 (17.8) 
 
Other 118 (11.8) 
 
Unknown 80 (8) 
Survival Status Alive 624 (62.4) 
 
Dead 376 (37.6) 
Site  Right 461 (46.1) 
 
Left 363 (36.3) 
 
Rectum 147 (14.7) 
 
Other 29 (2.9) 
Final stage 1 161 (16.1) 
 
2 402 (40.2) 
 
3 319 (31.9) 
 
4 118 (11.8) 
Primary tumour T1 74 (7.4) 
 
T2 106 (10.6) 
 
T3 526 (52.6) 
 
T4 294 (29.4) 
Lymph node metastasis N0 570 (57) 
 
N1 243 (24.3) 
 
N2 161 (16.1) 
Metastasis No metastasis 881 (88.1) 
 
With metastasis 119 (11.9) 
Vascular invasion Absent 502 (50.2) 
 
Present 483 (48.3) 
Grade 1 20 (2) 
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Clinical Variable Condition Number (%) 
 
2 886 (88.6) 
 
3 93 (9.3) 
Perineural invasion Absent 783 (78.3) 
 
Present 183 (18.3) 
Intramural lymphovascular invasion Absent 641 (64.1) 
 
Present 287 (28.7) 
Tumour edge Infiltrative 395 (39.5) 
 
Pushing 367 (36.7) 
Tumour budding score Low 508 (50.8) 
 
High 243 (24.3) 
Peritumoural lymphocytes Inconspicuous 549 (54.9) 
 
Conspicuous 217 (21.7) 
MMR Status  Unknown 22 (2.2) 
 
Proficient 818 (81.8) 
 
Deficient 160 (16) 
Age dichotomised Young 63 (6.3) 
 
Old 937 (93.7) 
Grade dichotomised Low 906 (90.6) 
 
High 93 (9.3) 
Site dichotomised Right side 490 (49) 
 
Left side 510 (51) 
 
Statistical analysis of c-Myc 
Average c-Myc expression for nuclear and stromal staining was calculated by 
taking the mean of the H-scores of each region of the tumour (luminal, central 
and advancing edge) and cytoplasmic staining was calculated as percentage of 
positive cells. To ensure the maximum number of data points, means were 
calculated where possible, and where only one location was present, this 
measurement was included in the results.  
Nuclear staining 
All distributions of nuclear c-Myc staining showed a skew to the right as seen 
in figure 7, due to the high frequency of zeroes for c-Myc expression. Therefore, 
medians and interquartile ranges (IQR) were presented. The median of the 
nuclear average H-score was 54 (IQR 12.5-102.5), which did not differ greatly 
from the medians of the luminal, central and advancing edge nuclear H-score 
medians (55 (IQR 10-110), 53 (IQR 10-100) and 50 (IQR 10-105) respectively). 
The correlation of each tumour region with nuclear average H-score was 
assessed using Spearman’s rank correlation, which shows that the tumour 
regions were very strongly positively correlated (>0.9) with the average nuclear 
H-score (p <0.001).  
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Figure 7: Distribution of nuclear H-scores. All nuclear H-scores were right-skewed, and average nuclear 
H-score was representative of the individual tumour regions.  
Associations between c-Myc nuclear staining and clinical variables 
The primary functions of c-Myc are performed in the nucleus and this is where 
the most biologically relevant staining was expected to be observed. Nuclear 
average H-score was re-coded into new negative and positive expression 
variables by the median (54) cut-off. Due to the skewed distribution of the data, 
additional splits were also performed in order to increase the number of 
significant observations that could be made. These included nuclear lowest 
tertile, nuclear highest tertile, and nuclear positive. To establish which 
variables may be linked to expression of c-Myc, Chi-squared analysis was 
performed with the clinical variables described in table 4. 
When the data was split by the median expression, the variables 5 year survival 
and site dichotomised were significantly associated with nuclear average H-
score. 5 year survival was negatively associated with c-Myc expression (p 
<0.001), and patients with positive c-Myc expression were more likely to have 
died after 5 years. Tumour location was also significantly associated with c-Myc 
expression. Negative c-Myc expression showed an association with right-sided 
tumours (p 0.03).  
When the data was dichotomised by the lowest tertile (above and below 26.33) 
poor 5 year survival was significantly associated with positive c-Myc expression 
(p <0.001), as seen with the median split. The presence of intratumoural 
lymphovascular invasion was associated with positive expression of c-Myc (p 
0.015). Splitting the data by highest tertile (above and below 85.33) once again 
showed a negative association between c-Myc expression and survival (p 
<0.001), with positive expression of c-Myc being indicative of death. Primary 
tumour stage showed a negative association with c-Myc expression (p 0.006), 
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with positive c-Myc expression associated with T1-3. T4 was associated with 
negative nuclear c-Myc expression.  
Table 4: Chi-square analysis of nuclear c-Myc positive and negative samples 




3 year Survival Alive 353 (76.2) 329 (71.2) 682 (73.7) 1.7 -1.7 3.020 
(0.082)  
Dead 110 (23.8) 133 (28.8) 243 (26.3) -1.7 1.7 
 
 
Total 463 (100) 462 (100) 925 (100) 
   
5 year Survival Alive 240 (51.7) 166 (35.9) 406 (43.8) 4.8 -4.8 23.45 
(<0.001)  
Dead 224 (48.3) 296 (64.1) 520 (56.2) -4.8 4.8 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Synchronous 
met  




52 (11.2) 52 (11.3) 104 (11.2) 0 0 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Recurrence  No 
Recurrence 
336 (72.4) 327 (70.8) 663 (71.6) 0.6 -0.6 0.304 
(0.581)  
Recurrence 128 (27.6) 135 (29.2) 263 (28.4) -0.6 0.6 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Cause of death  Alive 300 (64.7) 283 (61.3) 583 (63) 1.1 -1.1 6.899 
(0.075)  
CRC 69 (14.9) 92 (19.9) 161 (17.4) -2 2 
 
 
Other 53 (11.4) 59 (12.8) 112 (12.1) -0.6 0.6 
 
 
Unknown 42 (9.1) 28 (6.1) 70 (7.6) 1.7 -1.7 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Survival Status Alive 300 (64.7) 283 (61.3) 583 (63) 1.1 -1.1 1.147 
(0.284)  
Dead 164 (35.3) 179 (38.7) 343 (37) -1.1 1.1 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Final stage 1 70 (15.1) 83 (18) 153 (16.5) -1.2 1.2 2.610 
(0.456)  
2 200 (43.1) 178 (38.5) 378 (40.8) 1.4 -1.4 
 
 
3 142 (30.6) 150 (32.5) 292 (31.5) -0.6 0.6 
 
 
4 52 (11.2) 51 (11) 103 (11.1) 0.1 -0.1 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Primary 
tumour 
T1 26 (5.6) 44 (9.5) 70 (7.6) -2.3 2.3 6.934 
(0.074)  
T2 53 (11.4) 47 (10.2) 100 (10.8) 0.6 -0.6 
 
 
T3 241 (51.9) 249 (53.9) 490 (52.9) -0.6 0.6 
 
 
T4 144 (31) 122 (26.4) 266 (28.7) 1.6 -1.6 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Lymph node 
metastasis 
N0 274 (60.2) 261 (58.7) 535 (59.4) 0.5 -0.5 1.420 
(0.492)  
N1 105 (23.1) 117 (26.3) 222 (24.7) -1.1 1.1 
 
 
N2 76 (16.7) 67 (15.1) 143 (15.9) 0.7 -0.7 
 
 
Total 455 (100) 445 (100) 900 (100) 
   
Metastasis No metastasis 412 (88.8) 410 (88.7) 822 (88.8) 0 0 0.001 
(0.981) 





52 (11.2) 52 (11.3) 104 (11.2) 0 0 
 
 
Total 464 (100) 462 (100) 926 (100) 
   






Absent 228 (49.6) 244 (54.1) 472 (51.8) -1.4 1.4 1.877 
(0.171)  
Present 232 (50.4) 207 (45.9) 439 (48.2) 1.4 -1.4 
 
 
Total 460 (100) 451 (100) 911 (100) 
   
Grade 1 9 (1.9) 9 (2) 18 (1.9) 0 0 0.574 
(0.751)  
2 421 (90.7) 412 (89.4) 833 (90.1) 0.7 -0.7 
 
 
3 34 (7.3) 40 (8.7) 74 (8) -0.8 0.8 
 
 
Total 464 (100) 461 (100) 925 (100) 
   
Perineural 
invasion 
Absent 364 (80) 360 (82.2) 724 (81.1) -0.8 0.8 0.699 
(0.403)  
Present 91 (20) 78 (17.8) 169 (18.9) 0.8 -0.8 
 
 
Total 455 (100) 438 (100) 893 (100) 




Absent 297 (71.7) 301 (66.6) 598 (69.1) 1.6 -1.6 2.678 
(0.102) 
 
Present 117 (28.3) 151 (33.4) 268 (30.9) -1.6 1.6 
 
 
Total 414 (100) 452 (100) 866 (100) 
   
Tumour edge Infiltrative 155 (53.3) 210 (50.2) 365 (51.5) 0.8 -0.8 0.629 
(0.428)  
Pushing 136 (46.7) 208 (49.8) 344 (48.5) -0.8 0.8 
 
 
Total 291 (100) 418 (100) 709 (100) 
   
Tumour 
budding score 
Low 197 (69.9) 272 (65.1) 469 (67) 1.3 -1.3 1.745 
(0.187)  
High 85 (30.1) 146 (34.9) 231 (33) -1.3 1.3 
 
 
Total 282 (100) 418 (100) 700 (100) 
   
Peritumoural 
lymphocytes 
Inconspicuous 217 (73.8) 290 (69) 507 (71) 1.4 -1.4 1.905 
(0.168)  
Conspicuous 77 (26.2) 130 (31) 207 (29) -1.4 1.4 
 
 
Total 294 (100) 420 (100) 714 (100) 
   
MMR Status  
 
3 (0.6) 3 (0.6) 6 (0.6) 0 0 4.763 
(0.092)  
Proficient 399 (86) 373 (80.7) 772 (83.4) 2.1 -2.1 
 
 
Deficient 62 (13.4) 86 (18.6) 148 (16) -2.2 2.2 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Age 
dichotomised 
Young 25 (5.4) 31 (6.7) 56 (6) -0.8 0.8 0.712 
(0.399)  
Old 439 (94.6) 431 (93.3) 870 (94) 0.8 -0.8 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
Grade 
dichotomised 
Low 430 (92.7) 421 (91.3) 851 (92) 0.8 -0.8 0.572 
(0.449)  
High 34 (7.3) 40 (8.7) 74 (8) -0.8 0.8 
 
 
Total 464 (100) 461 (100) 925 (100) 
   
Site 
dichotomised 
Right side 242 (52.2) 208 (45) 450 (48.6) 2.2 -2.2 4.716 
(0.03)  
Left side 222 (47.8) 254 (55) 476 (51.4) -2.2 2.2 
 
 
Total 464 (100) 462 (100) 926 (100) 
   
*Significant p values (<0.05) are highlighted in bold 
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Mismatch repair status 
Patients who were c-Myc positive showed a higher association with dMMR 
than pMMR. c-Myc expression has been known to interact with mismatch 
repair status [48, 49]. To ensure that MMR status was not confounding the 
results, the Chi-square analysis was repeated, with the data split into pMMR 
and dMMR. Some samples did not have MMR status available (data not 
shown). Repetition of the analysis with MMR status yielded additional results. 
5 year survival was significant as before, but the split demonstrated that 
patients who had negative nuclear c-Myc expression and were pMMR, were 
statistically more likely to survive (p<0.001) than those who were dMMR (p 
0.033). 3 year survival in MMR deficient patients was significantly higher in c-
Myc positive patients (p 0.039) but not in MMR proficient patients (p 0.426). 
Lower primary tumour stage was associated with positive c-Myc expression (p 
0.019), and right-sided tumours were associated with low expression of nuclear 
c-Myc (p 0.003). These results were previously masked in the general analysis.  
As c-Myc is believed to be regulated by MLH1 and MSH2, the relationship 
between c-Myc expression and the status of these two genes was investigated. 
Median expression of c-Myc in proficient MLH1 (pMLH1) patients was 50 
(interquartile range 89.67) and the median expression of MLH1 deficient 
(dMLH1) patients was 70.8 (interquartile range 80.2). Mann-Whitney U test 
was used to assess if the difference in expression of c-Myc between pMLH1 and 
dMLH1 patients was significant. dMLH1 patients were found to have higher 
expression of c-Myc than pMLH1 patients (p 0.012). MSH2 has been reported 
to be regulated by the c-Myc MAX complex, and so the nuclear average H-score 
for MSH2 proficient (pMSH2) and deficient (dMSH2) patients were compared. 
As only 9 patients were dMSH2, these results may not be truly representative 
of the population. The median expression of pMSH2 patients was 52.59 
(interquartile range 88.88) and the median expression of dMSH2 patients was 
75 (interquartile range 82.5). Mann-Whitney U analysis revealed that there was 
no significant difference between the two groups (p 0.731).  
Survival analysis of c-Myc expression 
In the Chi-squared analysis above, interestingly, 3 year survival was not 
significantly different between the two groups (p 0.082) whereas 5 year 
survival was (p <0.001). To understand the importance of c-Myc expression on 
overall survival, Kaplan-Meier survival analysis was performed as seen in figure 
8. Nuclear average H-scores split by median expression and tertiles were 
compared with 3 year survival and 5 year survival. When the data was split by 
median expression, 3 year survival was not significantly different (p 0.099) but 
5 year survival (p <0.001) and death relating to CRC (p 0.006) were. After 5 
years, c-Myc negative patients had a 51.7% chance of survival, whereas c-Myc 
positive patients had a 35.9% chance of survival. When death was related to 
colorectal cancer, there was an approximately 86% chance of survival in the c-
Myc negative group after 5 years, whereas the positive group had a worse 
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chance of survival of approximately 77%. Median survival could not be 
calculated as most cases either survived or death was not related to CRC. When 
the data was divided into three tertiles, 5 year survival was significant (p 0.001). 
The lowest tertile had a 53.2% chance of survival, whereas the middle tertile 
had a 42.7% chance and the highest expressing group had a 35.6% chance of 
survival.  
 
Figure 8: Kaplan-Meier analysis of nuclear c-Myc expression split by median (left) and tertiles (right). 5 
year survival was significantly associated with nuclear c-Myc expression (middle), as was death relating 
to CRC (bottom). 3 year survival was not significantly associated with nuclear c-Myc (top). 
In order to further understand the relationship between c-Myc nuclear 
expression and survival, Cox regression analysis was performed using c-Myc 
nuclear average median split, in a multivariate analysis with the variables that 
c-Myc had shown significant association with. This was to determine whether 
c-Myc expression was truly related to survival or whether one of the clinical 
variables was confounding the analysis. Primary tumour stage, lymph node 
metastasis, grade, intratumoural lymphovascular invasion, perineural invasion, 
tumour edge, grade dichotomised and site dichotomised variables were 
assessed alongside c-Myc nuclear expression. Death related to colorectal 
cancer was assessed. The hazard ratio of nuclear average H-score in univariate 
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analysis revealed that death was 1.346 times more likely in c-Myc positive 
patients (p 0.007). Multivariate analysis revealed an even stronger difference 
(hazard ratio 1.6, p 0.001). In addition to this, primary tumour size, lymph node 
metastasis, grade and perineural invasion were significantly associated with 
survival. T3 tumours were significantly associated with death relating to CRC (p 
0.001) as were N2 tumours (metastasis to >6 nodes) (p 0.003). Presence of 
perineural invasion (p 0.047) and pushing tumour edge (p 0.039) were 
indicative of increased risk of death by CRC. Intratumoural lymphovascular 
invasion and site dichotomised were not significantly associated with survival 
status.  
Table 5: Cox regression analysis of c-Myc nuclear expression and significantly associated variables 
Variable Hazard 
ratio 
95.0% CI p value 
Lower Upper 
Nuc Average H-Score Median Split 1.346 1.084 1.67 0.007 
Clinical variable Hazard 
ratio 
95.0% CI  
Lower Upper P value 
Primary tumour 1T1* - - - 0.000 
Primary tumour T2 1.451 0.397 5.304 0.573 
Primary tumour T3 2.607 0.817 8.325 0.106 
Primary tumour T4 7.077 2.194 22.830 0.001 
Lymph node metastasisN0 - - - 0.005 
Lymph node metastasisN1 1.050 0.763 1.444 0.765 
Lymph node metastasisN2 1.695 1.202 2.391 0.003 
Grade 1 - - - 0.003 
Grade2 0.756 0.235 2.429 0.638 
Grade 3 1.486 0.440 5.019 0.524 
Perineural invasion 1.384 1.004 1.909 0.047 
Intramural lymphovascular invasion 0.765 0.572 1.022 0.070 
Tumour edge 0.729 0.539 0.984 0.039 
Site dichotomised 0.883 0.679 1.149 0.354 
Grade dichotomised**    - 
Nuclear Average H-Score Median 
Split 
1.600 1.226 2.087 0.001 
*Significant associations (p <0.05) highlighted in bold  
**Could not be determined 
 
Cytoplasmic expression of c-Myc 
Luminal, central and advancing edge cytoplasmic percentage positive cells 
were averaged to produce the cytoplasmic average positive score. The data 
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was skewed to the right for all cytoplasmic data including normal samples, as 
seen in figure 9. Median expression of average cytoplasmic staining was 2 (IQR 
0-15). Luminal, central and advancing edge medians were all 0, with IQRs of 0-
15, 0-10 and 0-10 respectively. Spearman’s rank correlation was used to 
analyse the similarity of the average data to the individual tumour samples. 
Luminal, central and advancing edge samples were highly positively correlated 
with the averaged cytoplasmic data (>0.75, p<0.001). Average cytoplasmic 
percentage positive was split by positive/negative expression due to low 
median expression.  
 
Figure 9: Distribution of percentage positive cytoplasmic staining for luminal, central, advancing edge 
and average tumours. 
Association with clinical variables 
Chi-squared analysis was performed as for nuclear H-score data. When the data 
was split by negative versus positive cytoplasmic c-Myc expression, increased 
lymph node metastasis was associated with negative cytoplasmic c-Myc 
expression (p 0.003). The presence of perineural invasion (p 0.024) was again 
associated with negative cytoplasmic c-Myc. In addition, site dichotomised was 
also significantly associated with cytoplasmic c-Myc expression (p 0.026). 
Tumours that originated in the left side of the colon were associated with 
positive cytoplasmic c-Myc expression.  
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Table 6: Chi-squared analysis of cytoplasmic expression of c-Myc expression against clinical 
variables 




Gender Female 152 (42.8) 253 (44.3) 405 (43.7) -0.4 0.4 0.198 
(0.656)  
Male 203 (57.2) 318 (55.7) 521 (56.3) 0.4 -0.4 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
3 year Survival Alive 258 (72.7) 424 (74.4) 682 (73.7) -0.6 0.6 0.330 
(0.566)  
Dead 97 (27.3) 146 (25.6) 243 (26.3) 0.6 -0.6 
 
 
Total 355 (100) 570 (100) 925 (100) 
   
5 year Survival Alive 146 (41.1) 260 (45.5) 406 (43.8) -1.3 1.3 1.727 
(0.189)  
Dead 209 (58.9) 311 (54.5) 520 (56.2) 1.3 -1.3 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Synchronous 
metastasis  




37 (10.4) 67 (11.7) 104 (11.2) -0.6 0.6 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Recurrence  No 
Recurrence 
253 (71.3) 410 (71.8) 663 (71.6) -0.2 0.2 0.031 
(0.86)  
Recurrence 102 (28.7) 161 (28.2) 263 (28.4) 0.2 -0.2 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Cause of death  Alive 216 (60.8) 367 (64.3) 583 (63) -1.1 1.1 2.336 
(0.506)  
CRC 65 (18.3) 96 (16.8) 161 (17.4) 0.6 -0.6 
 
 
Other 42 (11.8) 70 (12.3) 112 (12.1) -0.2 0.2 
 
 
Unknown 32 (9) 38 (6.7) 70 (7.6) 1.3 -1.3 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Survival Status Alive 216 (60.8) 367 (64.3) 583 (63) -1.1 1.1 1.103 
(0.294)  
Dead 139 (39.2) 204 (35.7) 343 (37) 1.1 -1.1 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Final stage 1 55 (15.5) 98 (17.2) 153 (16.5) -0.7 0.7 3.121 
(0.373)  
2 139 (39.2) 239 (41.9) 378 (40.8) -0.8 0.8 
 
 
3 124 (34.9) 168 (29.4) 292 (31.5) 1.8 -1.8 
 
 
4 37 (10.4) 66 (11.6) 103 (11.1) -0.5 0.5 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Primary 
tumour 
T1 26 (7.3) 44 (7.7) 70 (7.6) -0.2 0.2 0.704 
(0.872)  
T2 36 (10.1) 64 (11.2) 100 (10.8) -0.5 0.5 
 
 
T3 186 (52.4) 304 (53.2) 490 (52.9) -0.3 0.3 
 
 
T4 107 (30.1) 159 (27.8) 266 (28.7) 0.8 -0.8 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Lymph node 
metastasis* 
N0 192 (55.5) 343 (61.9) 535 (59.4) -1.9 1.9 11.43 
(0.003)  
N1 81 (23.4) 141 (25.5) 222 (24.7) -0.7 0.7 
 
 
N2 73 (21.1) 70 (12.6) 143 (15.9) 3.4 -3.4 
 
 
Total 346 (100) 554 (100) 900 (100) 
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37 (10.4) 67 (11.7) 104 (11.2) -0.6 0.6 
 
 
Total 355 (100) 571 (100) 926 (100) 
   






Absent 173 (49.4) 299 (53.3) 472 (51.8) -1.1 1.1 1.292 
(0.256)  
Present 177 (50.6) 262 (46.7) 439 (48.2) 1.1 -1.1 
 
 
Total 350 (100) 561 (100) 911 (100) 
   
Perineural 
invasion 
Absent 266 (77.3) 458 (83.4) 724 (81.1) -2.3 2.3 5.127 
(0.024)  
Present 78 (22.7) 91 (16.6) 169 (18.9) 2.3 -2.3 
 
 
Total 344 (100) 549 (100) 893 (100) 




Absent 226 (70.2) 372 (68.4) 598 (69.1) 0.6 -0.6 0.308 
(0.579) 
 
Present 96 (29.8) 172 (31.6) 268 (30.9) -0.6 0.6 
 
 
Total 322 (100) 544 (100) 866 (100) 
   
Tumour edge Infiltrative 115 (51.3) 250 (51.5) 365 (51.5) -0.1 0.1 0.003 
(0.959)  
Pushing 109 (48.7) 235 (48.5) 344 (48.5) 0.1 -0.1 
 
 
Total 224 (100) 485 (100) 709 (100) 
   
Tumour 
budding score 
Low 141 (64.4) 328 (68.2) 469 (67) -1 1 0.987 
(0.321)  
High 78 (35.6) 153 (31.8) 231 (33) 1 -1 
 
 
Total 219 (100) 481 (100) 700 (100) 
   
Peritumoural 
lymphocytes 
Inconspicuous 158 (69) 349 (72) 507 (71) -0.8 0.8 0.663 
(0.415)  
Conspicuous 71 (31) 136 (28) 207 (29) 0.8 -0.8 
 
 
Total 229 (100) 485 (100) 714 (100) 
   
MMR Status  
 
2 (0.6) 4 (0.7) 6 (0.6) -0.3 0.3 0.066 
(0.968)  
Proficient 296 (83.4) 476 (83.4) 772 (83.4) 0 0 
 
 
Deficient 57 (16.1) 91 (15.9) 148 (16) 0 0 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Age 
dichotomised 
Young 16 (4.5) 40 (7) 56 (6) -1.6 1.6 2.405 
(0.121)  
Old 339 (95.5) 531 (93) 870 (94) 1.6 -1.6 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
Grade 
dichotomised 
Low 321 (90.4) 530 (93) 851 (92) -1.4 1.4 1.948 
(0.163)  
High 34 (9.6) 40 (7) 74 (8) 1.4 -1.4 
 
 
Total 355 (100) 570 (100) 925 (100) 
   
Site 
dichotomised 
Right side 189 (53.2) 261 (45.7) 450 (48.6) 2.2 -2.2 4.969 
(0.026)  
Left side 166 (46.8) 310 (54.3) 476 (51.4) -2.2 2.2 
 
 
Total 355 (100) 571 (100) 926 (100) 
   
*Significant p values (<0.05) highlighted in bold 
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Survival analysis of cytoplasmic c-Myc expression 
3 year survival, 5 year survival and death related to colorectal cancer were 
assessed with cytoplasmic c-Myc staining. No significant difference could be 
observed between survival of positive or negative cytoplasmic c-Myc 
expressors, as seen in the Kaplan-Meier diagrams in figure 10. Cox regression 
analysis was done to assess whether 5 year survival stratified by cytoplasmic 
staining was affected by other variables. Perineural invasion, lymph node 
metastasis and site dichotomised were analysed with cytoplasmic staining. In 
the multivariate analysis, increased lymph node invasion led to increased 
survival (p <0.001), whereas the presence of perineural invasion was associated 
with increased risk of death (p 0.007), as were tumours that originated in the 
right side of the colon (p 0.026). Cytoplasmic staining was not significantly 
associated with survival outcome either in univariate or multivariate analysis.  
Table 7: Cox regression analysis of c-Myc cytoplasmic staining with significantly associated 
variables 
Variable Hazard ratio 95.0% CI p value  
Lower Upper 
Cytoplasmic average Positive only 0.937 0.755 1.164 0.558 
Clinical variable Hazard ratio 95.0% CI for Hazard ratio p value 
Lower Upper 
Lymph node metastasis N0* -   <0.001 
Lymph node metastasis N1 0.459 0.361 0.585 <0.001 
Lymph node metastasis N2 0.568 0.438 0.737 <0.001 
Perineural invasion 1.363 1.089 1.705 0.007 
Site dichotomised 0.816 0683 0.975 0.026 
Cytoplasmic average positive only 1.020 0.850 1.223 0.832 
*Significant associations highlighted in bold 
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Figure 10: Kaplan-Meier analysis of survival after 3 and 5 years, and death relating to colorectal cancer, 
stratified by c-Myc cytoplasmic average percentage positive cells. 
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Stromal expression of c-Myc 
The stromal H-scores were not normally distributed, as seen below in figure 11, 
and the median average expression of c-Myc in the stroma was 6.67 (IQR 2.5-
13.5). Luminal, central and advancing edge medians were all 5 (IQR 2-14, 1-13 
and 1-13.25 respectively). The luminal, central and advancing edge H-scores 
were strongly positively correlated with the average H-score (>0.75, p <0.001), 
demonstrating homogeneity of the staining.  
 
Figure 11: Distribution of c-Myc expression in the stroma. The data was not normally distributed, but 
was highly correlated between tumour regions and average H-score. 
Stromal c-Myc H-score Chi-squared analysis 
Chi-square analysis was performed with the clinical variables against the c-Myc 
stromal average H-score split by median (6.67) and by lowest and highest 
tertiles (data not shown). 3 year survival (p 0.012) and survival status (p 0.002) 
were associated with positive c-Myc stromal expression. Positive c-Myc stromal 
expression was associated with lower final stage (p 0.007), primary tumour 
stage (p 0.001) and lymph node metastasis (p 0.019). The absence of vascular 
invasion was associated with positive stromal c-Myc expression (p 0.018), as 
were conspicuous peritumoural lymphocytes (p <0.001).  
 
Table 8: Stromal average H-score median split 




Gender Female 212 (45.5) 193 (42) 405 (43.7) 1.1 -1.1 1.177 
(0.278)  
Male 254 (54.5) 267 (58) 521 (56.3) -1.1 1.1 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
3 year Survival* Alive 326 (70.1) 356 (77.4) 682 (73.7) -2.5 2.5 6.334 
(0.012)  
Dead 139 (29.9) 104 (22.6) 243 (26.3) 2.5 -2.5 
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Total 465 (100) 460 (100) 925 (100) 
   




5 year Survival Alive 197 (42.3) 209 (45.4) 406 (43.8) -1 1 0.939 
(0.333)  
Dead 269 (57.7) 251 (54.6) 520 (56.2) 1 -1 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Synchronous 
metastasis  




55 (11.8) 49 (10.7) 104 (11.2) 0.6 -0.6 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Recurrence  No 
Recurrence 
322 (69.1) 341 (74.1) 663 (71.6) -1.7 1.7 2.882 
(0.09)  
Recurrence 144 (30.9) 119 (25.9) 263 (28.4) 1.7 -1.7 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Cause of death  Alive 271 (58.2) 312 (67.8) 583 (63) -3 3 11.62 
(0.009)  
CRC 91 (19.5) 70 (15.2) 161 (17.4) 1.7 -1.7 
 
 
Other 59 (12.7) 53 (11.5) 112 (12.1) 0.5 -0.5 
 
 
Unknown 45 (9.7) 25 (5.4) 70 (7.6) 2.4 -2.4 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Survival Status Alive 271 (58.2) 312 (67.8) 583 (63) -3 3 9.285 
(0.002)  
Dead 195 (41.8) 148 (32.2) 343 (37) 3 -3 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Final stage 1 58 (12.4) 95 (20.7) 153 (16.5) -3.4 3.4 12.23 
(0.007)  
2 193 (41.4) 185 (40.2) 378 (40.8) 0.4 -0.4 
 
 
3 160 (34.3) 132 (28.7) 292 (31.5) 1.8 -1.8 
 
 
4 55 (11.8) 48 (10.4) 103 (11.1) 0.7 -0.7 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Primary tumour T1 20 (4.3) 50 (10.9) 70 (7.6) -3.8 3.8 17.39 
(0.001)  
T2 48 (10.3) 52 (11.3) 100 (10.8) -0.5 0.5 
 
 
T3 248 (53.2) 242 (52.6) 490 (52.9) 0.2 -0.2 
 
 
T4 150 (32.2) 116 (25.2) 266 (28.7) 2.3 -2.3 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Lymph node 
metastasis 
N0 255 (55.8) 280 (63.2) 535 (59.4) -2.3 2.3 7.961 
(0.019)  
N1 115 (25.2) 107 (24.2) 222 (24.7) 0.4 -0.4 
 
 
N2 87 (19) 56 (12.6) 143 (15.9) 2.6 -2.6 
 
 
Total 457 (100) 443 (100) 900 (100) 
   




55 (11.8) 49 (10.7) 104 (11.2) 0.6 -0.6 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Vascular 
invasion 
Absent 221 (47.9) 251 (55.8) 472 (51.8) -2.4 2.4 5.604 
(0.018)  
Present 240 (52.1) 199 (44.2) 439 (48.2) 2.4 -2.4 
 
 
Total 461 (100) 450 (100) 911 (100) 
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Absent 361 (79.5) 363 (82.7) 724 (81.1) -1.2 1.2 1.464 
(0.226)  
Present 93 (20.5) 76 (17.3) 169 (18.9) 1.2 -1.2 
 
 
Total 454 (100) 439 (100) 893 (100) 




Absent 292 (69.4) 306 (68.8) 598 (69.1) 0.2 -0.2 0.036 
(0.85) 
 
Present 129 (30.6) 139 (31.2) 268 (30.9) -0.2 0.2 
 
 
Total 421 (100) 445 (100) 866 (100) 
   
Tumour edge Infiltrative 170 (54) 195 (49.5) 365 (51.5) 1.2 -1.2 1.404 
(0.236)  
Pushing 145 (46) 199 (50.5) 344 (48.5) -1.2 1.2 
 
 
Total 315 (100) 394 (100) 709 (100) 
   
Tumour 
budding score 
Low 203 (66.3) 266 (67.5) 469 (67) -0.3 0.3 0.107 
(0.743)  
High 103 (33.7) 128 (32.5) 231 (33) 0.3 -0.3 
 
 
Total 306 (100) 394 (100) 700 (100) 
   
Peritumoural 
lymphocytes 
Inconspicuous 254 (80.4) 253 (63.6) 507 (71) 4.9 -4.9 24.18 
(<0.001)  
Conspicuous 62 (19.6) 145 (36.4) 207 (29) -4.9 4.9 
 
 
Total 316 (100) 398 (100) 714 (100) 
   
MMR Status  
 
1 (0.2) 5 (1.1) 6 (0.6) -1.7 1.7 7.225 
(0.027)  
Proficient 402 (86.3) 370 (80.4) 772 (83.4) 2.4 -2.4 
 
 
Deficient 63 (13.5) 85 (18.5) 148 (16) -2.1 2.1 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Age 
dichotomised 
Young 27 (5.8) 29 (6.3) 56 (6) -0.3 0.3 0.106 
(0.745)  
Old 439 (94.2) 431 (93.7) 870 (94) 0.3 -0.3 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
Grade 
dichotomised 
Low 427 (91.6) 424 (92.4) 851 (92) -0.4 0.4 0.174 
(0.677)  
High 39 (8.4) 35 (7.6) 74 (8) 0.4 -0.4 
 
 
Total 466 (100) 459 (100) 925 (100) 
   
Site 
dichotomised 
Right side 220 (47.2) 230 (50) 450 (48.6) -0.8 0.8 0.721 
(0.396)  
Left side 246 (52.8) 230 (50) 476 (51.4) 0.8 -0.8 
 
 
Total 466 (100) 460 (100) 926 (100) 
   
*Significant p values (<0.05) highlighted in bold  
 
Survival analyses of stromal c-Myc expression 
Kaplan-Meier analysis was performed using 3 year survival, 5 year survival and 
death caused by colorectal cancer as defining events, stratified by positive and 
negative stromal c-Myc H-score and by highest tertile. 3 year survival was 
significantly higher for positive stromal c-Myc (p 0.009), with negative stromal 
c-Myc expression having an approximately 70% chance of death after 3 years 
and c-Myc positive patients having a roughly 77% chance of survival. There was 
no significant difference between 3 year survival if the data was stratified by 
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highest tertile (p 0.094). There was no significant difference between survival 
at 5 years regardless if the split was by median (p 0.133) or highest tertile (p 
0.255). Death relating to CRC was significantly different when the data was 
stratified by highest tertile (p 0.026), with stromal c-Myc negative patients 
having a 79% chance of survival and stromal c-Myc positive having an 86% 
chance of survival. When split by median (p 0.062) there was no significant 
difference.  
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Figure 12: Kaplan-Meier analysis of stromal c-Myc expression. 3 year survival and death relating to 
colorectal cancer were significantly related to c-Myc stromal expression. 
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Table 9: Cox regression analysis of stromal c-Myc expression and significantly associated variables 
Variable Hazard 
ratio 
95.0% CI p value 
Lower Upper 
Stromal Average Median split 0.753 0.608 0.933 0.01 
Clinical Variable Hazard 
ratio 
95.0% CI p value 
Lower Upper 
Final Stage 1* 
   <0.001 
Final Stage 2 0.001 0 6.82E+20 0.807 
Final Stage 3 0.001 0 5.01E+20 0.798 
Final Stage 4 0.002 0 1.17E+21 0.822 
Primary tumour T1 
   <0.001 
Primary tumour T2 1.218 0.334 4.449 0.765 
Primary tumour T3 1550.767 0 1E+27 0.793 
Primary tumour T4 3135.546 0 2.03E+27 0.774 
Lymph node metastasis N0 
   0.004 
Lymph node metastasisN1 1.193 0.677 2.103 0.54 
Lymph node metastasis N2 2.017 1.138 3.577 0.016 
Vascular invasion 1.095 0.802 1.496 0.569 
Peritumoural lymphocytes 0.821 0.602 1.119 0.212 
Recurrence  2.971 2.168 4.072 <0.001 
MMR Status  
   <0.001 
MMR Status Proficient 1.165 0.161 8.4 0.88 
MMR Status Deficient 2.329 0.318 17.075 0.406 
Site dichotomised 0.88 0.675 1.148 0.345 
Stromal Average Median split 0.832 0.645 1.074 0.158 
*Significant associations highlighted in bold 
 
Cox regression analysis was performed with stromal c-Myc expression and in 
univariate analysis was significantly associated with 5 year survival (p 0.01). 
Increased primary tumour stage (p<0.001) and lymph node metastasis (p 
0.004) were associated with poorer survival, as was recurrence (p <0.001). 
Stromal c-Myc expression was not significantly associated with survival in the 
multivariate analysis (p 0.158), despite there being a higher risk of death in the 
c-Myc negative group in the univariate analysis (p 0.01). This suggests that c-
Myc stromal expression is confounded by other clinical variables.  
Does the staining intensity of one cellular compartment affect the staining in 
another area? 
c-Myc is expected to be expressed in the nucleus, as it plays an important role 
in controlling transcription and increasing expression of 15% of the genome. 
The analysis performed here however shows that c-Myc can also be expressed 
in the cytoplasm. It is important to understand if the expression of one cellular 
compartment is related to the expression in another, in order to be able to 
effectively use c-Myc as a biomarker. The scatter plot in figure 13 below shows 
that there is a moderate correlation between nuclear average H-score and 
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cytoplasmic average positive percentage. The Spearman’s rank correlation 
showed a moderately positive (0.429), significant (p<0.001) correlation. This 
suggests that patients who are nuclear c-Myc positive may also be positive for 
cytoplasmic c-Myc. The median H-score of 54 was used as the cut-off for 
nuclear expression as it showed a significant association with survival. The 75th 
percentile of positive cytoplasmic staining was used to avoid including non-
specific background staining. This is shown in the following groups: 
 
Table 10: Combination of c-Myc expression in the nucleus and in the cytoplasm 
 Nuclear (%) 
Below median Above median 
Cytoplasmic (%) Below 75th percentile 486 (48.6) 272 (27.2) 
Above 75th percentile 49 (0.49) 193 (19.3) 
 
 
Figure 13: Scatter plot showing the relationship between c-Myc nuclear and cytoplasmic H-scores. 
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Statistical analysis of CD44 
Membrane staining of CD44 
Average membrane H-score was calculated from luminal, central and 
advancing edge samples. 86 were excluded due to insufficient data for all three 
individual tumour regions. The distribution of all membrane H-scores showed 
a right-skew as seen in figure 14. The median expression of membrane average 
H-score was 15 (IQR 0-57.5), and the average H-score was highly correlated 
(Spearman’s rank >0.8) with all three tumour regions. Luminal, central and 
advancing edge samples all showed a median of 20 (IQR 0-85, 0-75 and 0-75, 
respectively). In the normal colon, expression of CD44 tended to be observed 
in the base of the crypts only (as seen in figure 5), associated with stem cells. 
This is expected given the role CD44 plays in colonic stem cell maintenance 
[68].  
 
Figure 14: Distribution of CD44 membrane staining in individual tumour regions and average H-scores.  
Membrane Chi-square analysis 
As the median H-score of CD44 was so low in the membrane, it is possible that 
any staining artefact present could influence the results. For this reason, the 
data was assessed with an average H-score cut-off of 57.5 (75th percentile). 
Mismatch repair status was very strongly associated with expression of CD44 
(p <0.001) and high CD44 expression was associated with MMR deficient 
tumours. Mismatch repair status is important in determining treatment of 
colorectal cancer [84], and may influence which pathways are involved in 
tumourigenesis. Because of this, the data were categorised into mismatch 
repair proficient and deficient prior to Chi-squared analysis. The results are 
displayed in the table below alongside the ungrouped data.  
The analysis returned a number of significant associations with high 
membranous CD44 expression without differentiating between mismatch 
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repair status, including with females, (p 0.009), poor 5 year survival (p 0.001) 
and no metastasis (p 0.003). Lack of recurrence was weakly associated with 
high CD44 expression (p 0.004), as were right-sided tumours (p 0.011). High 
final stage and primary tumour stage were associated with low CD44 
expression (p 0.001 and <0.001 respectively). High CD44 expression was 
associated with the absence of vascular invasion (p <0.001), and a pushing 
tumour edge (p <0.001), as well as showing weak association with conspicuous 
peritumoural lymphocytes (p 0.04).  
When the data were categorised by the MMR status into proficient (pMMR) or 
deficient (dMMR), several of the clinical variables showed differences between 
the two groups. In pMMR patients, 3 year survival was significantly higher in 
high expressors of CD44 than in patients with low CD44 expression (p 0.032), 
whereas it did not differ in the uncategorised data. 5 year survival was 
significantly higher in low expressors of CD44 (p 0.01), but less so than when 
the data was uncategorised (p 0.001). Metastasis (p 0.015) was significantly 
associated with low CD44 expression in pMMR patients, although less so than 
in the uncategorised data (p 0.003). The association between low primary 
tumour stage and high CD44 expression increased in the pMMR group 
compared to the uncategorised data (p <0.001). Vascular invasion (p <0.001) 
was associated with low CD44 membrane expression in the proficient patients, 
as was an infiltrative tumour edge (p 0.016).  
Only gender was specific to MMR deficient patients, with female patients 
having higher expression of membranous CD44 (p 0.013). Grade dichotomised 
showed a stronger association between high grade (poorly differentiated 
tumours) and low CD44 expression in dMMR patients (p 0.008) as opposed to 
pMMR patients (p 0.034). Some associations which were significant before 
distinguishing between MMR status were lost in this analysis. This includes 
recurrence, which although marginally significant without differentiating for 
MMR status (p 0.04), was not significantly associated with CD44 expression in 
pMMR (p 0.073) or dMMR (p 0.955) patients alone. Peritumoural lymphocytes 
also lost their significance after mismatch repair status was accounted for. 
Finally, right-sided tumours were significantly associated with high CD44 
membranous expression prior to MMR status split, at which point almost 
perfectly opposite expression could be observed in MMR proficient (p 0.348) 
and deficient (p 0.377) groups (see table 11). Only grade dichotomised was 
significantly associated with CD44 expression in the two MMR groups but not 
in the overall analysis. In pMMR patients, high CD44 expression was enriched 
in well differentiated tumours and low CD44 expression was enriched poorly 
differentiated tumours (p 0.034), whereas in dMMR patients high CD44 
expression was enriched in patients with low grade tumours and low CD44 
expression was enriched in high grade, poorly differentiated tumours (p 0.008). 
Age, tumour budding score, cause of death, lymph node metastasis, perineural 
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invasion and intratumoural vascular invasion did not show any association with 
CD44 membrane expression. 
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Survival analysis of average CD44 membrane H-scores 
Kaplan-Meier analysis was used to measure survival status at 3 and 5 years, and 
in the case of death relating to colorectal cancer, as seen in figure 15. The data 
was dichotomised by 75th percentile and stratified by MMR status. 3 year 
survival was not significantly different (p 0.101) between patients with low and 
high expression of membranous CD44, even considering MMR status. Median 
survival could not be calculated but 71.9% of patients survived to three years 
with low CD44, and 80.4% with high CD44 in the pMMR group. Approximately 
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72.5% of patients survived with low CD44 and 68.7% survived with high CD44 
in the dMMR group. There was a significant difference in 5 year survival 
between high and low expressors of membranous CD44 (p 0.022). In pMMR 
patients, low expression of membranous CD44 led to improved 5 year survival 
(median 56.4 months, confidence intervals not computed) over high 
membranous CD44 expression (51.8 months 95% CI 49-55 months). In dMMR 
patients, 5 year survival was also higher in patients expressing low 
membranous CD44 (55.7 months 95% CI 48-64 months), than in patients with 
high membranous CD44 (51.3 months 95% CI 46-57 months). The 5 year 
survival curves in pMMR patients crossed over at approximately 40 months, 
casting some doubt on the reliability of true significance of the results. The 
statistical analysis was repeated using the Tarone-Ware method [85], instead 
of the log rank test used in previous analyses, and showed a non-significant 
relationship (p 0.102) between CD44 expression and survival. Death related to 
CRC was not significantly different between high and low CD44 membranous 
expression (p 0.615). Approximate 5 year survival for patients with low or high 
CD44 membrane expression in pMMR patients was 80.5% and 82.2% and in 
dMMR was 84.7 and 84.3 in dMMR.  
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Figure 15: Kaplan-Meier survival curves for CD44 membrane staining split by 75th percentile and stratified 
by MMR status, with MMR proficient patients on the left and MMR deficient patients on the right. 
Univariate and multivariate Cox regression analyses were performed on overall 
survival to assess whether average membrane CD44 staining was associated 
with survival or whether the effects on survival were due to other factors, as 
seen in table 12. All data was stratified by MMR status. Overall survival was not 
significantly related to increased membranous CD44 staining in univariate 
analysis (p 0.483) but was when included in multivariate analysis (p 0.035). 
Recurrence significantly increased the risk of death (p <0.001), as did increased 
primary tumour stage (p <0.001) and grade dichotomised (p <0.001). Pushing 
tumour edge led to a significantly lower hazard ratio (p 0.035) and better 
survival.  
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Table 12: Cox regression analysis of CD44 staining and significantly associated variables 
Variable Hazard ratio 95.0% CI  p value 
Lower Upper 
Mean Membrane H-Score 75th 
Percentile 
0.91 0.7 1.184 0.483 
 
Hazard Ratio 95.0% CI  p value 
Lower Upper 
Mean Membrane H-Score 75th 
Percentile* 
1.387 1.023 1.88 0.035 
Gender 1.174 0.904 1.524 0.228 
Synchronous metastasis 1.602 0.454 5.652 0.464 
Recurrence  2.715 1.982 3.718 <0.001 
Final Stage 
   
0.896 
Final Stage (1) 0.561 0.07 4.525 0.587 
Final Stage (2) 0.519 0.066 4.091 0.534 
Final Stage (3) 0.452 0.026 7.986 0.588 
Primary tumour T1 
   
<0.001 
Primary tumour T2 1.16 0.315 4.27 0.823 
Primary tumour T3 2.513 0.24 26.28 0.442 
Primary tumour T4 5.353 0.509 56.24 0.162 
Metastasis 1.595 0.151 16.867 0.698 
Vascular invasion 1.181 0.872 1.598 0.283 
Tumour edge 0.717 0.526 0.978 0.035 
Peritumoural lymphocytes 0.741 0.536 1.023 0.069 
Grade Dichotomised 2.221 1.497 3.295 <0.001 
Site Dichotomised 0.972 0.741 1.275 0.839 
*Significant results (p <0.05) highlighted in bold 
 
Independent tumour region expression: survival analysis 
5 year survival was analysed for individual tumour regions split at the 75th 
percentile to see if the crossing of survival curves observed in figure 15 was due 
to differences in the tumour regions. As seen in figure 16 below, the curves for 
the individual tumour regions still cross over. 5 year survival was not 
significantly different in luminal tumour samples, when assessed by Tarone-
Ware analysis (p 0.186). Advancing edge tumours showed an earlier crossover, 
around 46 months, and survival was not significantly different (p 0.543). In the 
central tumour region, high and low CD44 membrane expressors crossed over 
at multiple points (approximately 19 and 44 months) and survival was 
significantly different by Tarone-Ware analysis (p 0.034). Individual tumour 
regions did not show distinct survival patterns in Kaplan-Meier curves, 
reflective of the lack of heterogeneity shown in the correlation analysis. 
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Figure 16: Survival analysis of individual tumour regions. Membrane-specific CD44 staining was assessed 
in 3 year survival, 5 year survival and death relating to colorectal cancer. 
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Cytoplasmic staining of CD44 
Cytoplasmic staining was assessed by a H-score on a scale of 0-200, unlike other 
staining compartments, as the staining did not reach a high level of intensity. 
The distribution of the data was normal, and therefore the mean and standard 
deviation are presented in the table below. The data was split by median 
average cytoplasmic expression (58.33) in order to be consistent with other 
analyses and to ensure an equal split of positive and negative expressors.  


















Included 771 743 690 572 914 
Excluded 229 257 310 428 86 
Mean 50.26 45.76 43.01 30.07 61.88 
Median 40 40 35 20 58.3333 
Std. Deviation 43.15 40.09 38.71 33.82 43.63 












0.51 (0.231) - 
 
Chi-squared analysis of cytoplasmic CD44 
After the average cytoplasmic data was split by the median, it was compared 
with the clinical variables to determine if there was any association. The results 
are demonstrated in table 14 below. 3 year survival was significantly associated 
with positive cytoplasmic CD44 expression (p 0.002), as was the lack of 
metastasis (p 0.001), no recurrence (p <0.001) and overall survival (p 0.001). 
Higher final stage was associated with negative cytoplasmic CD44 (p <0.001), 
as was primary tumour stage (p <0.001) and lymph node metastasis (p <0.001). 
Absence of metastasis (p 0.001) and vascular invasion (p <0.001) were 
associated with positive CD44 expression. Presence of perineural invasion (p 
<0.001) and intratumoural lymphovascular invasion (p 0.005) were associated 
with negative cytoplasmic CD44. “Pushing” tumour edge (p 0.001) and dMMR 
(p 0.005) were both associated with positive cytoplasmic CD44 expression. 
Poorly differentiated tumours were associated with negative cytoplasmic CD44 
expression (p <0.001). 
  
Page 57 of 89 
 
Table 14: Chi-square analysis of cytoplasmic CD44 expression 




Gender Female 189 (41.8) 211 (45.7) 400 (43.8) -1.2 1.2 1.381 
(0.24)  
Male 263 (58.2) 251 (54.3) 514 (56.2) 1.2 -1.2 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
3 year 
Survival* 
Alive 310 (68.6) 358 (77.7) 668 (73.2) -3.1 3.1 9.569 
(0.002)  
Dead 142 (31.4) 103 (22.3) 245 (26.8) 3.1 -3.1 
 
 
Total 452 (100) 461 (100) 913 (100) 
   
5 year Survival Alive 201 (44.5) 190 (41.1) 391 (42.8) 1 -1 1.043 
(0.307)  
Dead 251 (55.5) 272 (58.9) 523 (57.2) -1 1 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Synchronous 
metastasis  
1 386 (85.4) 426 (92.2) 812 (88.8) -3.3 3.3 10.68 
(0.001)  
2 66 (14.6) 36 (7.8) 102 (11.2) 3.3 -3.3 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Recurrence  No 
Recurrence 
301 (66.6) 356 (77.1) 657 (71.9) -3.5 3.5 12.37 
(<0.001)  
Recurrence 151 (33.4) 106 (22.9) 257 (28.1) 3.5 -3.5 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Cause of death  Alive 259 (57.3) 314 (68) 573 (62.7) -3.3 3.3 12.88 
(0.005)  
CRC 95 (21) 63 (13.6) 158 (17.3) 3 -3 
 
 
Other 56 (12.4) 52 (11.3) 108 (11.8) 0.5 -0.5 
 
 
Unknown 42 (9.3) 33 (7.1) 75 (8.2) 1.2 -1.2 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Survival Status Alive 259 (57.3) 314 (68) 573 (62.7) -3.3 3.3 11.11 
(0.001)  
Dead 193 (42.7) 148 (32) 341 (37.3) 3.3 -3.3 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Final stage 1 50 (11.1) 97 (21) 147 (16.1) -4.1 4.1 28.42 
(<0.001)  
2 177 (39.2) 199 (43.1) 376 (41.1) -1.2 1.2 
 
 
3 159 (35.2) 131 (28.4) 290 (31.7) 2.2 -2.2 
 
 
4 66 (14.6) 35 (7.6) 101 (11.1) 3.4 -3.4 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Primary 
tumour 
T1 20 (4.4) 47 (10.2) 67 (7.3) -3.3 3.3 28.59 
(<0.001)  
T2 40 (8.8) 58 (12.6) 98 (10.7) -1.8 1.8 
 
 
T3 232 (51.3) 256 (55.4) 488 (53.4) -1.2 1.2 
 
 
T4 160 (35.4) 101 (21.9) 261 (28.6) 4.5 -4.5 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Lymph node 
metastasis 
N0 241 (53.7) 287 (65.4) 528 (59.5) -3.6 3.6 17.05 
(<0.001)  
N1 115 (25.6) 101 (23) 216 (24.3) 0.9 -0.9 
 
 
N2 93 (20.7) 51 (11.6) 144 (16.2) 3.7 -3.7 
 
 
Total 449 (100) 439 (100) 888 (100) 
   
Metastasis No metastasis 386 (85.4) 426 (92.2) 812 (88.8) -3.3 3.3 10.68 
(0.001) 





66 (14.6) 36 (7.8) 102 (11.2) 3.3 -3.3 
 
 
Total 452 (100) 462 (100) 914 (100) 
   






Absent 197 (43.9) 268 (59.6) 465 (51.7) -4.7 4.7 22.13 
(<0.001)  
Present 252 (56.1) 182 (40.4) 434 (48.3) 4.7 -4.7 
 
 
Total 449 (100) 450 (100) 899 (100) 
   
Perineural 
invasion 
Absent 328 (74.2) 383 (87.2) 711 (80.7) -4.9 4.9 24.03 
(<0.001)  
Present 114 (25.8) 56 (12.8) 170 (19.3) 4.9 -4.9 
 
 
Total 442 (100) 439 (100) 881 (100) 




Absent 266 (64.6) 320 (73.4) 586 (69.1) -2.8 2.8 7.738 
(0.005) 
 
Present 146 (35.4) 116 (26.6) 262 (30.9) 2.8 -2.8 
 
 
Total 412 (100) 436 (100) 848 (100) 
   
Tumour edge Infiltrative 189 (57.1) 159 (44.5) 348 (50.6) 3.3 -3.3 10.84 
(0.001)  
Pushing 142 (42.9) 198 (55.5) 340 (49.4) -3.3 3.3 
 
 
Total 331 (100) 357 (100) 688 (100) 
   
Tumour 
budding score 
Low 210 (64.8) 246 (69.5) 456 (67.3) -1.3 1.3 1.680 
(0.195)  
High 114 (35.2) 108 (30.5) 222 (32.7) 1.3 -1.3 
 
 
Total 324 (100) 354 (100) 678 (100) 
   
Peritumoural 
lymphocytes 
Inconspicuous 246 (74.5) 248 (68.7) 494 (71.5) 1.7 -1.7 2.892 
(0.089)  
Conspicuous 84 (25.5) 113 (31.3) 197 (28.5) -1.7 1.7 
 
 
Total 330 (100) 361 (100) 691 (100) 
   
MMR Status  Proficient 393 (86.9) 364 (78.8) 757 (83.6) 3.1 -3.1 9.814 
(0.002)   
Deficient 56 (12.4) 92 (19.9) 148 (16.4) -3.1 3.1 
 
 
Total 452 (100) 462 (100) 905 (100) 
   
Age 
dichotomised 
Young 34 (7.5) 30 (6.5) 64 (7) 0.6 -0.6 0.371 
(0.542)  
Old 418 (92.5) 432 (93.5) 850 (93) -0.6 0.6 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
Grade 
dichotomised 
Low 399 (88.3) 437 (94.8) 836 (91.6) -3.5 3.5 12.56 
(<0.001)  
High 53 (11.7) 24 (5.2) 77 (8.4) 3.5 -3.5 
 
 
Total 452 (100) 461 (100) 913 (100) 
   
Site 
dichotomised 
Right side 204 (45.1) 243 (52.6) 447 (48.9) -2.3 2.3 5.095 
(0.024)  
Left side 248 (54.9) 219 (47.4) 467 (51.1) 2.3 -2.3 
 
 
Total 452 (100) 462 (100) 914 (100) 
   
*Significant associations (p<0.05) highlighted in bold 
 
Survival analysis of cytoplasmic CD44 
Survival relating to cytoplasmic CD44 staining was assessed using Kaplan-Meier 
curves and Cox regression analyses. The average H-scores were split by tertiles, 
in order to show the difference in the wide distribution of H-scores. 3 year 
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survival (p 0.001) was significantly associated with positive CD44 cytoplasmic 
staining status. Death relating to colorectal cancer (p 0.005) was negatively 
significantly associated with cytoplasmic CD44 expression, as shown in figure 
17, with more patients surviving CRC if they were positive for cytoplasmic 
CD44. Median survival was incalculable as more than 50% of patients survived 
beyond 3 years, and only a small proportion of patients died directly as a result 
of CRC. 66.9% of patients survived to 3 years with low cytoplasmic CD44, 
whereas 72.6% survived with medium cytoplasmic CD44 and 81.4% survived if 
they showed high expression. Death related to colorectal cancer showed a 
similar upward trend relating to increase in cytoplasmic CD44, with 77% of low 
expressing patients surviving to 5 years, 81.3% of medium expressing patients 
surviving to 5 years and 87% surviving with high cytoplasmic expression. 43.5% 
of low and medium expressors survived to 5 years, and 40.9% of high 
expressing cytoplasmic CD44 patients survived to 5 years. This is similar to what 
was observed in membrane-specific expression of CD44. 5 year survival was 
not significantly related to cytoplasmic CD44 (p 0.910), and the highest tertile 
crossed the other two at 50 months, similar to membranous CD44. 
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Figure 17: Kaplan-Meier survival analysis of low, medium and high expressors of cytoplasmic CD44 in 
relation to 3 year survival, 5 year survival and death relating to colorectal cancer.  
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Univariate Cox regression analysis revealed a significant association between 
increasing cytoplasmic H-score and survival (p 0.01). However, this trend was 
not present in multivariate analysis (p 0.945). Increased recurrence (p <0.001), 
primary tumour stage (p <0.001), lymph node metastasis (p 0.017) and grade 
dichotomised (p 0.013) were all associated with increased hazard ratios. 
Patients with MMR deficiency showed a worse survival than MMR proficient 
patients (p 0.01).  
Table 15: Cox regression analysis of cytoplasmic CD44 staining with significantly associated 
variables 
Variable Hazard Ratio 95.0% CI p value 
Lower Upper 
Mean Cyto H-Score Tertiles Split* 0.836 0.729 0.959 0.01 
Variables Hazard Ratio 95.0% CI p value 
Lower Upper 
Synchronous metastasis  1.405 0.41 4.813 0.588 
Recurrence  2.844 2.07 3.906 <0.001 
Final Stage 1 
   0.239 
Final Stage 2 0.815 0.101 6.588 0.848 
Final Stage 3 0.491 0.062 3.916 0.502 
Final Stage 4 0.519 0.029 9.218 0.655 
Primary tumour T1 
   <0.001 
T2 1.129 0.307 4.152 0.855 
T3 1.762 0.17 18.304 0.635 
T4 3.568 0.341 37.314 0.288 
Lymph node metastasis 1.393 1.061 1.829 0.017 
Metastasis 1.644 0.153 17.659 0.681 
Perineural invasion 1.37 0.991 1.894 0.057 
Intramural lymphovascular invasion 0.864 0.648 1.151 0.318 
Tumour edge 0.759 0.554 1.039 0.086 
MMR status  1.665 1.132 2.449 0.01 
Grade Dichotomised 1.721 1.122 2.638 0.013 
Site Dichotomised 0.946 0.72 1.244 0.693 
Mean Cyto H-Score Tertiles Split 1.006 0.845 1.199 0.945 
*Significant results (p <0.05) highlighted in bold 
 
Visual observations 
Different types of staining could be observed for cytoplasmic CD44. A blanket-
like staining was observed in some tumours, but in others a more granular 
pattern could be seen. Examples of the staining patterns are shown in figure 
18. Granular staining was typically observed close to the basolateral edge of 
the cells, where the cells interact with the stroma, as opposed to the apical 
edge, facing the lumen. Given that CD44 acts as a mediator between stromal 
and epithelial factors, this seems to be true staining. When the staining was 
observed in the granular pattern, it was difficult at times to discern if it was 
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membranous or cytoplasmic. For the purposes of this study all granular staining 
was counted as cytoplasmic.  
 
Figure 18: Cytoplasmic CD44 staining in colorectal cancer. The staining may be granular (A) or diffuse (B). 
Granular staining was often found near the basolateral edge of the cells near the stroma. 
Nuclear staining of CD44 
Nuclear CD44 staining was highly unusual and only occurred in four patients. 
No patients had nuclear staining in the normal-adjacent region. Because the 
number of patients with nuclear expression was so low, any statistical analyses 
would have been inconclusive and therefore were not performed.  
Stromal staining of CD44 
Stromal staining of CD44 was normally distributed. The mean average stromal 
H-score was 49.39 (standard deviation 27.72). The luminal, central and 
advancing edge samples were all strongly positively correlated with the 
average H-score (Pearson’s correlation above 0.75) as seen in table 16 below.  
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Included 770 743 690 914 
Excluded 230 257 310 86 
Mean 49.85 49.64 47.73 49.39 
Std. Deviation 33.55 34.34 34.15 27.72 
Range 170 200 190 165 
Median 45 45 40 47.5 
Interquartile range 48 50 50 38.42 
Pearson's correlation 
with mean stromal H-
score (p value) 
0.796 (<0.001) 0.786 (<0.001) 0.791 (<0.001) - 
 
Chi-square analysis of stromal CD44 with clinical variables 
To perform Chi-squared analysis, the data were initially split by median 
expression, as in previous analyses. However this returned no significant 
associations with any of the clinical variables and therefore the average H-score 
data was split by tertiles (low 0-35, medium 35-60, high 60-300). The results 
are shown in the table below and demonstrate that 5 year survival increases 
with decreasing expression of CD44 (p 0.005). This was not the case for 3 year 
survival (p 0.367) or survival status (p 0.523). The presence of peritumoural 
lymphocytes was associated with increased stromal CD44 (p 0.001), confirming 
the expression of CD44 in lymphocytes. 
Table 17: Chi-square analysis of stromal CD44 expression with clinical variables 
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*Significant associations (p <005) highlighted in bold 
 
Page 66 of 89 
 
Survival analysis of stromal CD44 
Kaplan-Meier and Cox regression analyses were performed to further 
understand the relationship between stromal CD44 staining and survival. 
Kaplan-Meier analysis was performed with the CD44 stromal staining split into 
tertiles, looking at 3 year survival, 5 year survival and death related to 
colorectal cancer, as seen in figure 19. 3 year survival was not significantly 
associated with stromal CD44 expression (p 0.443), and neither was death 
relating to colorectal cancer (p 0.672). 5 year survival could not be calculated 
for patients expressing low levels of stromal CD44, and did not differ much 
between medium (53.9 months) and high expression (51.8 months) but was 
significantly different (p 0.022). Univariate Cox regression analysis did not show 
a significant association between stromal CD44 and overall survival (p 0.475). 
Multivariate analysis revealed a slightly stronger but still not significant 
association (p 0.363). MMR status was not significantly associated with survival 
(p 0.102) but the presence of peritumoural lymphocytes led to worse outcome 
(hazard ratio 0.569, p <0.001). 
Page 67 of 89 
 
 
Figure 19: Kaplan-Meier analysis of stromal CD44 expression revealed a significant association with 5 year 
survival, but not with 3 year survival or death relating to CRC. 
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CD44 and c-Myc interaction 
c-Myc and CD44 are known to share common pathways and interactions in 
colorectal cancer. Chi-square analysis showed that the patients with the 
highest expression of CD44 are associated with the highest expression of c-Myc 
(p <0.001). The data of both were then combined (see the method used to 
combine c-Myc nuclear and cytoplasmic staining), using the median cut-off for 
nuclear c-Myc expression and the 75th percentile for CD44 expression. Good 5 
year survival was associated with c-Myc-/CD44- patients (p <0.001), whereas 
the lowest primary tumour stage was associated with c-Myc+/CD44+ patients. 
A lack of metastasis was associated with high CD44 expression, regardless of c-
Myc expression (p 0.018). The presence of vascular invasion was most strongly 
associated with patients who were c-Myc-/CD44- (p <0.001). Right sided 
tumours showed a high affiliation with cMyc-/CD44+, whereas left-sided 
tumours were associated with c-Myc+/CD44- expression (p 0.002). These 
associations reveal that although CD44 and c-Myc do share some common 
pathways, they also act independently, leading to different clinical outcomes. 
 
Table 18: Nuclear c-Myc expression and Membranous CD44 expression combined with clinical 







































































































































































































































     


































































































































































































































































































































































































































































































     
*Significant results (p <0.05) highlighted in bold 
 
Tumour stroma content as a biomarker 
Tumour stromal content is considered an important biomarker in colorectal 
cancer. Stromal content was determined as the percentage of the core 
occupied by stromal cells rather than epithelial cells. The consensus molecular 
subtype CMS4 tumours are characterised by a high stromal content [26]. 
Tumour epithelium content was assessed prior to evaluating CD44 and c-Myc 
staining, and stromal content was calculated by taking the percentage of 
epithelium away from 100. The average tumour stromal content was normally 
distributed as seen in figure 20, with a mean of 49.39 (standard deviation 27.7). 
The data was split by median expression (47.5) in keeping with the previous 
analyses of c-Myc and CD44 staining, and the association with clinical variables 
assessed by Chi-square analysis.  
 
Figure 20: Distribution of average stromal content in CD44 and c-Myc stained slides. Average stromal 
content was calculated from average epithelial content and shows a normal distribution. 
Chi-square analysis of tumour stroma content 
Tumour stromal content was compared to the clinical data using a median cut-
off. High tumour stromal content was associated with increased metastasis (p 
0.013), increased primary tumour stage (p <0.001) and increased lymph node 
metastasis (p 0.016). Increased final stage (p 0.002) was associated with high 
stromal content, and so it is unsurprising that alongside these associations, 
Page 71 of 89 
 
recurrence (p <0.001), poor 3 year survival (p 0.015) and poor survival status (p 
0.005) are also observed. Death related to colorectal cancer was associated 
with high stromal content (p 0.013). Vascular invasion (p 0.003), perineural 
invasion (p 0.004) and an infiltrative tumour edge (p 0.002) were all associated 
with high stromal content, as seen in table 19. 
 
Table 19: Chi-square analysis of tumour stromal content with clinical variables 
Clinical variable Condition Low High Total Adjusted residual Χ² (p 
value) 
Gender* Female 239 
(48.4) 
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Cause of death  Alive 330 
(66.8) 
278 (58) 608 (62.5) 2.8 -2.8 10.77 
(0.013)  
CRC 72 (14.6) 101 
(21.1) 
173 (17.8) -2.7 2.7 
 
 
Other 60 (12.1) 57 
(11.9) 
117 (12) 0.1 -0.1 
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800 (82.2) -1.4 1.4 
 
 
Deficient 91 (18.4) 65 
(13.6) 
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885 (91) -0.4 0.4 0.161 
(0.688)  
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473 (48.6) 1.6 -1.6 2.720 
(0.099)  












   
*Significant associations (p <0.05) highlighted in bold 
 
Survival analysis of tumour stroma content 
Survival of patients relating to tumour stromal content was assessed using the 
median cut-off. 3 year survival was significantly higher (p 0.017) in patients with 
low stromal content, with 76.5% of patients surviving to 3 years and 69.5% of 
patients with high stromal content surviving to the same time. Deaths relating 
to CRC were significantly lower in patients with low stromal content (p 0.005), 
with an 84.7% chance of surviving versus a 77% chance of survival in patients 
with high stromal content. 5 year survival was not significantly associated with 
tumour stroma content (p 0.110) but showed the same trend, as shown in 
figure 21.  
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Figure 21: Kaplan-Meier analysis of tumour stroma with 3 year survival, 5 year survival and death relating 
to CRC. Only 5 year survival was not significantly associated with survival. 
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Association with biomarkers 
Mann-Whitney U analysis was performed to assess the relationship between 
tumour stroma content and c-Myc and CD44 staining. c-Myc showed no 
association with stromal content (p 0.342), and the mean stromal content was 
very similar between positive (62.22, 95% CI 57-67) and negative (64.92, 95% 
CI 60-70) nuclear expression groups. CD44 however showed a strong 
relationship with stromal content (p <0.001), with low stromal content 
associated with high CD44 membranous staining. The mean average stromal 
content for low CD44 staining was 42.26% (95% CI 38-47), whereas the mean 
stromal content in CD44 high tumours was 28.69 (95% CI 25-33). When 
compared via multivariate Cox regression analysis it was clear that CD44 was 
not significantly associated with survival (p 0.897) whereas low stromal content 
was (p 0.020). 
Bioinformatic analysis of c-Myc and CD44 in the Cancer Genome Atlas 
c-Myc analysis 
In order to further understand the importance of c-Myc expression in 
colorectal cancer, TCGA colorectal cancer data was assessed for differential 
expression of genes associated with c-Myc. The log2 fold change of all genes 
was assessed in conjunction with c-Myc. Of the 60488 genes included, 9984 
had a log2 fold change of ±1. 8247 genes were significantly changed (p<0.05), 
and of those, 7872 were changed with an adjusted p value <0.05. This equates 
to approximately 13% of the genome, and is similar to published figures 
concerning c-Myc regulation. 11 genes were significantly downregulated, and 
the other 7861 were upregulated, demonstrating the involvement of c-Myc in 
stimulating gene expression rather than repressing it. Pathways significantly 
associated with c-Myc expression are shown in figure 22.  
Pathway analysis was performed in WebGestalt using KEGG, Panther and 
Reactome databases, as described in figure 6. 169 unique genes were shown 
to be significantly upregulated as part of pathways across KEGG, Panther and 
Reactome databases. 34 histone genes were found to be upregulated in the 
presence of c-Myc, and were seen across multiple pathways including 
Reactome pathways “pre-NOTCH transcription and translation”, and 
“formation of the β-catenin:TCF transactivating complex”, or KEGG pathway 
“Systemic lupus erythematosus”. This is in accordance with the β-catenin:TCF 
interaction regulating c-Myc overexpression in colorectal cancer [39]. The 
Panther “Wnt signalling” pathway was also upregulated. In addition, multiple 
pathways associated with metabolic processes including the “Ionotropic 
glutamate receptor pathway” and “vitamin D metabolism” and pathway were 
associated with c-Myc expression, demonstrating the role of c-Myc in 
metabolism and glycolysis in colorectal cancer. The “Cadherin” pathway, which 
includes TCF/LEF, EGFR and Wnt, was also significantly associated with c-Myc 
expression. 25 olfactory receptor genes were upregulated, such as OR51B4 and 
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OR2C3, which have been associated with cancer in the past [86, 87]. Of the 11 
genes which were downregulated, EYA1 is known to be repressed by Wnt 
signalling [88], and SFTPC downregulation has been linked to increased 
proliferation and progression in lung cancer [89].  
CD44 analysis 
TCGA colorectal cancer data was assessed for differential expression of genes 
associated with CD44 in the same way as for c-Myc. All genes were assessed 
for the log2 fold change of their expression in conjunction with CD44. Of the 
60488 genes included, 2268 had a log2 fold change of ±1. 1851 genes were 
significantly changed (p<0.05), and of those, 1693 showed differential 
expression with an adjusted p value <0.05. 74 genes showed downregulation 
and the other 1619 were upregulated. The upregulated genes were analysed 
using WebGestalt to determine the number of pathways significantly 
upregulated.  
Out of the top 10 KEGG, Panther and Reactome pathways, 87 unique genes 
were found to be upregulated. No Panther pathways had a significant FDR 
score (<0.05), and only 4 KEGG pathways did. The pathways that were enriched 
were associated with cholesterol metabolism, bile secretion, and fat digestion, 
among others. These pathways are associated with general gut processes [90], 
but are also upregulated in colorectal cancer stem cells [91, 92]. The pathway 
“Transcriptional regulation of pluripotent stem cells” specifically was 
upregulated, demonstrating this. All of these pathways are reminiscent of CD44 
in stem cell initiation and maintenance [71, 73, 93]. The “Melanogenesis” 
pathway was also upregulated, and genes such as PRKACG and WNT7A, known 
to be upregulated in CRC, were overexpressed [94, 95]. Additional genes such 
as CALML5 and CREB3L3 were also upregulated in this pathway, but have not 
been associated with colorectal cancer before. 
Analysis of differential expression of genes in the presence of CD44 and c-Myc 
in colorectal cancer in this way allowed an additional opportunity to 
understand their functions in this disease, and how they can act as possible 
targets for therapeutic agents. For example, disrupting the proliferation of 
cancer cells via suppression of c-Myc.  
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Figure 22: Pathways upregulated with regard to CD44 (upper) and c-Myc (lower) expression. Expected 
numbers of genes are in blue, observed number of genes in orange. No upregulated pathways were shared 
between CD44 and c-Myc. A higher number of pathways upregulated in the presence of c-Myc than in 
CD44. 
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Discussion 
This project was an opportunity to assess a large cohort of patients for c-Myc 
and CD44 expression, as well as tumour stroma content. As the samples were 
in TMA form, it was possible to assess heterogeneity of CD44 and c-Myc in 
colorectal cancer. High correlation of both proteins between the tumour 
regions showed that they were homogenously expressed. Histological analysis 
is highly subjective, but performing inter and intra-observer comparisons 
demonstrated that the data were robust. CD44 and c-Myc are most commonly 
expressed in the tumour epithelial membrane and nucleus respectively, but 
this study did not stop at these cellular compartments. By interrogating analysis 
in all cellular compartments where staining was present, including in stromal 
cells, further understanding of the clinical significance of these biomarkers in 
colorectal cancer could be obtained. An additional limitation of this study was 
the confounding effects of MMR status. By separating the mismatch repair 
proficient and deficient patients, it was possible to see the clinical significance 
of each protein without interference. 
c-Myc tumoural expression 
c-Myc is a well-studied protein in colorectal cancer, with functions in multiple 
pathways that lead to increased pathogenicity. It is associated with the CMS2 
molecular subtype and overexpression of the Wnt signalling pathway. The 
staining was assessed using the Y69 clone antibody, which is specific to the N-
terminal domain of c-Myc and should not react with the paralogues n-Myc and 
l-Myc (alignments checked using Uniprot, 15th September 2020) [96].  
As c-Myc is involved in transcriptional regulation, its expression is expected in 
the nucleus. When the nuclear expression of c-Myc was split into positive and 
negative expression, positive c-Myc expression was associated with poor 5 year 
survival, which was emphasised in MMR proficient patients. Death relating to 
colorectal cancer was significantly higher in c-Myc positive patients, even 
accounting for clinical variables. Cytoplasmic staining was generally weak and 
only associated with low lymph node status, absence of perineural invasion and 
left-sided tumours. It is possible that much of the c-Myc cytoplasmic staining 
was artefact, as the associations found were not strongly significant and were 
consistent with the nuclear staining trends.  
Some studies relating to c-Myc and survival show a tendency to disagree with 
the consensus molecular subtypes, and show worse survival with increased c-
Myc expression [97]. Other factors in this analysis, such as c-Myc being highly 
expressed in left-sided tumours, and primary and lymph node stages, show an 
agreement with the CMS subtyping in MMR proficient patients, but not 
regarding survival [26]. It may be that the multiple functions c-Myc plays in 
colorectal cancer have contradictory clinical results that ultimately lead to poor 
outcomes. An example is the role c-Myc plays in cancer stem cell maintenance, 
which would lead to increased risk of recurrence and overall poor survival [98], 
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but is not necessarily associated with metastasis [99]. Another possibility is that 
c-Myc expression was interpreted differently in other studies which using 
different antibodies and methodologies. The association between MLH1 
deficiency and c-Myc expression is supported by the literature [48] and could 
be driving proliferation and giving c-Myc positive cells a selective advantage. 
Stromal c-Myc expression was observed in multiple patients and staining was 
localised to the cytoplasm of plasma cells. The strong association with 
conspicuous peritumoural lymphocytes supports the possibility that, as plasma 
cells tend to be associated more with normal colon stroma than tumour 
stroma, this shows the presence of immune response [100, 101]. Indeed, high 
stromal c-Myc was associated with lower stage, primary tumour stage and 
lymph node metastasis, and was indicative of improved survival. Increased c-
Myc staining in the stroma may be informative of an active immune response 
and improved outcome.  
This study of 1000 primary tumours from CRC patients has demonstrated an 
interesting association with clinical outcomes. Further work could be pursued 
in order to demonstrate precisely which pathways are responsible for the 
influence of c-Myc expression on survival. This could include 
immunohistochemical comparison with other markers such as β-catenin and 
other proteins involved in Wnt signalling, or markers of proliferation and 
metastasis. As increased c-Myc expression is associated with chemoresistance 
[102, 103], comparing c-Myc expression in matched pre and post treatment 
patient samples may help to devise better treatment strategies for patients.  
CD44 tumoural expression 
CD44 proteins play multiple roles in the normal and cancerous colon. Its 
function in the interaction between tumour epithelium and stroma make it an 
interesting protein and potential biomarker. The immunohistochemical 
staining of the TMAs was performed with the antibody clone DF1485, which is 
described as reacting to the whole protein. CD44 however, is not one single 
protein, but multiple variants which are predictive of different clinical 
outcomes [56, 104]. CD44 staining is expected in multiple cellular 
compartments, including the membrane, cytoplasm and nucleus. Very little 
nuclear staining was observed in this study and could represent a rare 
population of colorectal cancer patients. CD44 interacts with its main ligand 
hyaluronic acid on the cell surface, and this is the main cellular compartment 
where staining is expected [55]. The association between CD44 expression and 
survival was inconclusive due to the crossing of the Kaplan-Meier curves. High 
membrane-specific staining was associated with low stage, lack of invasiveness 
and tumours originating in the right side of the colon, especially in MMR 
proficient patients. CD44 positive tumours could represent a CMS2-like 
population, given the relationship between CD44 and the Wnt-signalling 
pathway. Bioinformatic analysis revealed an association between increased 
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CD44 expression and loss of expression at ch18q21, a recognised feature of the 
canonical adenoma-carcinoma pathway [6], enriched in CMS2 tumours [26].  
Expression of CD44 in the cytoplasm was represented by granular and diffuse 
staining, and in future analyses it would be interesting to split the two groups 
to see if there were differences in clinical outcomes. As the granular staining 
was generally localised to the basolateral edge of cells, it could be that this 
represents an intracellular form of CD44, involved in detaching tumour 
epithelial cells from the extracellular matrix and leading to invasion and 
metastasis [63]. Studying this interaction could demonstrate the method by 
which CD44 regulates metastasis. High cytoplasmic CD44 was associated with 
low primary tumour stage, lack of metastasis and invasiveness, as was 
membranous staining. This is surprising as previous studies have suggested that 
CD44 is implicated in metastasis, due to its interaction with the extracellular 
matrix. Intracellular forms of CD44 are associated with detachment from the 
extracellular matrix and maintaining a stem cell state [63, 65]. Studies have 
shown that while increased CD44v6 is associated with worse survival and 
metastasis [105], increased CD44s is associated with better survival and lower 
primary tumour stage [106], as seen in this study. If the antibody used here 
detects multiple isoforms of CD44, it may be that the effect of one isoform is 
confounding the effect of the other. Use of antibodies specifically targeting the 
different isoforms could improve the reliability of the results.  
Lymphocytes are known to express CD44 [107] and so it is unsurprising that 
CD44 staining was found in the tumour stroma. Increased stromal CD44 
staining was associated with peritumoural lymphocytes and worse 5 year 
survival, although Cox regression analysis showed that this effect was 
confounded by the presence of peritumoural lymphocytes. Given that CD44 is 
expressed in these lymphocytes, it is possible that CD44 could be used in 
colorectal cancer as both a marker of cancer stem cells and as a marker of 
tumour infiltrating lymphocytes.  
Both c-Myc and CD44 have been studied extensively for their roles in colorectal 
cancer. By looking at their joint expression in tumours, it has provided an 
opportunity to understand which clinical variables are influenced by both 
proteins, and their shared pathways. CD44 and c-Myc feature in initiating and 
maintaining a stem-like state in colorectal cancer cells [108, 109]. This study 
demonstrates that although this may be true, there appears to be no impact 
on tumour stage or overall survival when the two are expressed together. 
Furthermore, there is an association between the expression of both 
biomarkers with low primary tumour stage and metastasis, suggesting that this 
population of c-Myc+/CD44+ tumours may have a good outcome.  
Tumour stroma content 
Tumour stroma content has a prognostic role in colorectal cancer. Increased 
stromal content is associated with CMS4, a mesenchymal molecular subtype 
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associated with EMT and the worst overall survival of the consensus molecular 
subtypes [26]. A median cut-off of 46.6% was used to determine high and low 
stromal content, consistent with other studies using a 50% cut-off [110]. 
Clinical variables associated with metastasis, including vascular invasion, and 
increased primary tumour stage were associated with stromal content. High 
stromal content was associated with poor survival, consistent with previous 
analyses [111, 112]. c-Myc expression did not show any significant association 
with tumour stroma content, but CD44 did. There was a higher level of CD44 
expression in the patients with low stroma, suggesting that the presence of 
CD44 is indicative of better outcomes, in agreement with the independent 
biomarker analysis. When the two were analysed in a multivariate Cox-
regression analysis, it became clear that the tumour stroma content was 
confounding the effects of CD44 on survival. Improving the stromal analysis 
could include measuring the stroma directly, either using digital image analysis 
or using antibodies to assess the content of fibroblasts or lymphocytes. 
 
Bioinformatic analyses 
This project represented an opportunity to investigate the expression of CD44 and c-
Myc in archived colorectal cancer samples. The samples used here do not have RNA 
data and access to other biomarker data, to supplement this work, was limited. The 
use of TCGA data therefore represented a chance to extend this work and understand 
which genes these proteins interact with in CRC. The upregulation of genes associated 
with proliferation and stem-state in the c-Myc analysis confirms what was seen in the 
literature regarding its functions in CRC. This analysis also offered an opportunity to 
look for previously unobserved connections, such as that between CD44 and CALM5 
and CREB3L3, which both belong to the Melanogenesis pathway. This could have 
significant repercussions when selecting therapies for colorectal cancer, as the 
Melanogenesis pathway has been associated with resistance to oxaliplatin [113]. Time 
constraints meant that further analyses could not be performed to interrogate these 
data, but this is something that could be pursued as a future work to enable enhanced 
understanding of the roles of c-Myc and CD44 in colorectal cancer. 
Conclusion 
This study presented an opportunity to study three different biomarkers of 
colorectal cancer. By analysing the expression of CD44 and c-Myc in stroma as 
well as epithelial cells, additional information about patient outcomes could be 
inferred. Future analyses could include assessing the relationships of other 
biomarkers with CD44 and c-Myc, to find the combination with the most 
prognostic value. Looking at both c-Myc and CD44 expression in matched 
metastatic and lymph node samples could enable better understanding of how 
these proteins are involved in the metastatic process. The findings here 
regarding CD44 contrasted with the existing literature. This demonstrates the 
importance of using variant-specific antibodies to study CD44 expression. c-
Myc positive tumours were found to have worse survival that c-Myc negative 
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tumours, knowledge which could be used to tailor treatment for patients of 
CRC. Finally, the analysis of tumour stroma content demonstrated the negative 
impact of stroma-rich tumours on clinical outcomes. 
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